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ITALIAN ABSTRACT 
 
 
La malattia di Alzheimer (AD) è caratterizzata dall'aggregazione del peptide β-amiloide (Aβ). 
Aβ deriva dalla proteina precursore dell'amiloide (APP), che può subire due vie di taglio 
proteolitico reciprocamente esclusive. La via amiloidogenica coinvolge l’attività di BACE e 
γ-secretasi e porta alla formazione di Aβ, mentre la via non amiloidogenica coinvolge 
ADAM10, una disintegrina e una metalloproteinasi 10, che scinde APP all’interno del 
dominio corrispondente ad Aβ, precludendone così la produzione. Recentemente, abbiamo 
identificato un nuovo partner di legame di ADAM10, AP2, che è responsabile 
dell'internalizzazione di ADAM10, influenzando quindi la sua attività. È interessante notare 
che la formazione del complesso ADAM10/AP2 è significativamente aumentata nel cervello 
dei pazienti con AD rispetto a soggetti sani, suggerendo un ruolo di ADAM10/AP2 nella 
patogenesi di AD. In questo contesto, abbiamo recentemente sviluppato un peptide 
permeabile alle cellule (denominato PEP3) in grado di interferire con l'associazione 
ADAM10/AP2. La somministrazione intraperitoneale di PEP3 in un modello murino di AD 
per due settimane è sicura ed efficace nel ridurre l'endocitosi di ADAM10 e, quindi, 
nell'incrementare la localizzazione sinaptica di ADAM10. La somministrazione di PEP3 nelle 
fasi avanzate di malattia è in grato di modificare parametri biochimici, come i livelli di Aβ e 
la composizione molecolare delle sinapsi, ma senza riuscire a produrre miglioramenti a 
livello di deficit cognitivo mostrato da questi animali. Invece, i risultati ottenuti nei test 
comportamentali suggeriscono un recupero della funzione cognitiva nei topi AD in fasi 
iniziali di malattia dopo la somministrazione di PEP3. Inoltre, ulteriori indagini hanno 
rivelato che il trattamento con PEP3 aumenta i livelli di una subunità del recettore NMDA e 
recupera la perdita e le alterazioni delle spine dendritiche osservati nei topi AD. Questi effetti 
sembrano essere mediati da un aumento dei livelli di sAPPα endogeno. Questi risultati 
positivi indicano l'internalizzazione di ADAM10 come potenziale bersaglio per lo sviluppo di 
una terapia efficace per l'AD. 
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ABSTRACT 
 
 
Alzheimer’s disease (AD) is characterized by the aggregation of amyloid beta peptide (Aβ). 
Aβ derives from the amyloid precursor protein (APP), which can undergo two mutually 
exclusive pathways. The amyloidogenic pathway involves BACE and γ-secretase activities 
and leads to Aβ formation. While, the non-amyloidogenic pathway involves ADAM10, a 
disintegrin and metalloproteinase 10, which cleaves APP within the domain corresponding to 
Aβ, thus precluding Aβ production. Recently, we identified a new ADAM10 binding partner, 
named AP2, which is responsible for ADAM10 internalization, therefore affecting its 
activity. Interestingly, ADAM10/AP2 interaction is significantly increased in AD patients' 
brain compared to healthy control subjects, suggesting a role of ADAM10/AP2 in AD 
pathogenesis. In this framework, we have recently developed a cell permeable peptide 
(named PEP3) capable of interfering with ADAM10/AP2 association. The intraperitoneal 
administration of this CPP to a mouse model of AD for two weeks is safe and effective in 
impairing ADAM10 endocytosis and, thereby, in increasing ADAM10 synaptic localization. 
At late stages of disease, the PEP3 administration is able to change biochemical parameters, 
as Aβ levels and the molecular composition of the synapses without ameliorating the 
cognitive deficits of these mice. On the other hand, at early stage of the pathology the 14-
days administration of the PEP3 rescues the cognitive impairment of the AD mice. Further 
investigations revealed that the synaptic levels of the NMDA receptor subunit GluN2A are 
increased upon the treatment and that previously observed shrinkage and dendritic spine loss 
in AD mice were improved after CPP treatment. These results are mediated by an increase in 
endogenous sAPPα. These positive results point to ADAM10 internalization as a potential 
target mechanism for the development of an effective AD therapy. 
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1. Alzheimer’s disease 
 
1.1. History of the research 
 
Across time and civilizations, the concept of mind and its perturbations has always been a 
topic of interest. The fact that aging could be associated with memory impairment was 
already present in ancient Egypt around 2000 years before our era.1 The idea that organic 
lesions could be the cause for cognitive deficits came later thanks to several writers of the 
Hellenistic Empire (Figure-1). Ancient Greek authors Galen (130–201 AD), Aretaeus of 
Cappadocia (2nd century AD) and Aulus Cornelius Celsus (1st century AD) wrote about 
Dementia and its potential causes. Among them, Aretaeus was the first to introduce a 
distinction between acute and chronic neurological disorders. Chronic disorders, dementia as 
referred to nowadays, were described by Aretaeus as characterized by irreversible impairment 
of higher cognitive functions. 
 
 
 
(Figure 1) A terracotta plaque, circa 460-450 before our era, depicts Odysseus (right), returning to his native Ithaca. 
Odysseus is shown approaching his wife Penelope, as members of his house- his father (Seated on the ground), Laertes; 
his son, Telemachus; and the swineherd Eumaios- look on. “Laertes not being able to recognize his son, could be 
imagined as an old patient affected by dementia, terribly in need of elements outside his memory, steadily placed in his 
orchard (his long-term memory), to accomplish the recognition of Odysseus.” Interesting depiction of Odysseus’s father 
(Laertes) as potentially suffering from dementia.2 Plaque in the collection of the Metropolitan Museum of Art, Fletcher 
Fund, 1930. (Photo credit: The Metropolitan Museum of Art, New York, website: 
https://www.metmuseum.org/art/collection/search/253053). 
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No discoveries or evolutions of the conceptualisation of brain diseases were made from that 
point until the 16th century. Scientific research on the brain and its disfunctions went through 
a long period of obscurantism during middle age. This medieval interlude was mainly due to 
the rise of the church and its theological doctrines.3 Therefore, it’s only very recently that 
technology with the invention of light microscopy, and scientific rationalization allowed 
scientist like Santiago Ramón y Cajal to get a glimpse of understanding of the brain and its 
constituents. In 1888, he first provided scientific evidences presenting the brain as made of 
independent cells.4 His work referred today as the “Neuron doctrine” lead to new empirical 
research techniques together with a better comprehension of the brain. Allowing scientists to 
methodologically bridge potential brain alterations to cognitive dysfunctions.5 
During beginning of the 20th century, Alois Alzheimer, a German psychiatrist born in 1864, 
was the first in 1906 to scientifically characterize a unknown pathology affecting memory.6 
In a six-volume study, the 'Histologic and Histopathologic Studies of the Cerebral Cortex,' he 
described this condition as consisting of aggregation of deposits in the cortex of 51-years-old 
woman, Auguste Deter, practicing neurology as we know it today by corelating organic brain 
alterations to cognitive symptoms.7 Those first histopathological evidences where the first 
grasped on the pathology later called by its first observer, Alzheimer’s disease (AD).  
 
1.2. Situation Nowadays 
 
Today, AD is known to be the most common form of dementia however still of unknown 
etiology. This chronic neurodegenerative disease is characterized by progressive cognitive 
deficits such as decline in memory, problem-solving, language and other cognitive skills that 
affects a person's ability to perform simple daily tasks.8 The severity of the cognitive deficits 
worsen as the neurodegeneration spread. Starting from the hippocampus, the neuronal death 
eventually affects other parts of the brain, including those that enable a person to carry out 
basic functions such as walking and swallowing. In the final stage of the disease, people are 
strongly incapacitated and require constant healthcare. AD leads ultimately to death due to 
complications such as pneumonia.9 The disease affects statistically more women than men in 
both prevalence and severity.10 The cause of this unbalance is still not fully understood, even 
though partly explained by women longer lifespan.  
 
INTRODUCTION 
 12 
The pathology is affecting an estimated of 14 million people worldwide, with a cost of 
approximately 105 billions euros per year.11 This is a global socio-economical health issue 
that touches not only the patients but also their family from a psychological and economical 
point of view.12 These numbers, together with the burden on public health and society, are 
expected to dramatically aggravate, due to the progressive rise of the life expectancy during 
the last century.13 Up to date this tremendous disorder is unfortunately incurable because of 
the scarce knowledge of the molecular events that drive the onset of the disease. However 
major advances have been made and science continues to evolve hand in hand with 
technology promising therapeutics to be developed. 
 
Thanks to the advent of genetic studies, AD can be divided in two groups now: the early-
onset AD (EOAD) and the late-onset AD (LOAD). The EOAD is diagnosed before the age of 
65 and represents only 2% of all the cases therefore it is considered extremely rare. The 
EOAD is a familiar form of AD triggered by genomic alteration through autosomal dominant 
mutations. Such mutations occur in three specific genes: Presenilin1 (PS1), Presenilin2 (PS2) 
and amyloid precursor protein (APP).14 On the contrary, the LOAD is the most common form 
of the disease. It is characterized by genetic predisposition that involves several genes 
polymorphisms (for instance Apolipoprotein E (APOE)),15 that are associated with an 
increased risk for AD, but are not sufficient to cause the pathology.16 Other risk-factors have 
been also identified as increasing risk of developing AD such as head injury in males, 
diabetes mellitus, smoking, and also a lower social engagement.17 Although carrying at least 
one APOE e4 allele increases the most the probability to develop the pathology.18  
 
 
1.3. Hallmarks of the pathology 
 
Studies of the pathological mechanisms of the disease have identified two markers as to be 
involved in the Disease and required for its diagnostic.19 The composition of those signature 
markers have been discovered during the 80s. Discovered in 1986, the neurofibrillary tangles 
(NFT) are mainly intracellular deposits due to the disassembling of tau proteins that then get 
hyperphosphorylated.20 Discovered in 1984, the Aβ plaques are mainly extra cellular and due 
to the processing of the APP by the β- and then g-secretase (Figure-2).21  
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(Figure 2) Neurofibrillary tangles (pointed with arrow) and amyloid plaque (marked with star) in cortex of famous patient 
Auguste Deter. Amyloid plaques are due to aggregation of amyloid-b peptide produced by b-secretase activity on APP. 
NFT are composed of aggregated hyperphosphorylated tau proteins. (Image credit: “Alzheimer A, Uber eine eigenartige 
Erkankung der Hirnrinde. Allg. Zschr. F Psychiatr. Psychisch- Gerichtl Mediz, 1907 64:p. 146-8.“) 
Research has enabled detailed understanding of the molecular pathogenesis of the hallmarks 
of the disease. It is known that the Amyloid plaques are formed of aggregated Aβ peptides. 
The formation of the Aβ peptide is the result of the cleavage of APP by the b-secretase 
BACE1 in the N-terminus domain. This cleavage leads to release of the soluble APPβ and 
formation of membrane embedded CTF99 fragment. The CTF99 fragment is then cleaved by 
the g-secretase which is a multi-subunit complex composed of Presenilin-1 (PS1), Presenilin-
2 (PS2), PEN2, Nicastrin, and APH1. This final cleavage by the g-secretase is leading to the 
production of Amyloid Intracellular Domain (AICD) and the formation of Ab peptide 
(figure-3). In pathological conditions, the overproduction of Aβ peptide is then leading to a 
succession of negative events consisting in the accumulation and aggregation of the peptide 
in neurotoxic amyloid plaques, the aggregation of hyperphosphorylated tau protein in NFTs 
and a serious neuronal loss together with a strong inflammatory response. Ab peptide ending 
at residue 42 being more prone to aggregation compared to Ab peptide ending at residue 40.22 
Some studies suggest that Ab40 could antagonize Ab42 tendency to aggregates putting the 
increase of Ab42 or Ab42/Ab40 ratio as a more relevant marker of the pathology.23 
INTRODUCTION 
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Moreover average plasma levels of Ab42 or Ab42/Ab40 ratio is known to be higher in 
prodromal stage of AD.24  
The Amyloid cascade has been proposed since now 25 years to be the major cause of 
cognitive dysfunction in AD. A second processing pathway of APP complex that counteracts 
the activity of the b-secretase BACE1 involves a different secretase whose activity do not 
lead to the production of the Ab peptide.25 This non-amyloidogenic pathway has for main 
protagonist the major α-secretase called A Disintregrin And Metalloprotease 10 (ADAM10). 
This sheddase is a member of the disintegrin and metalloprotease family and cleaves APP 
within the Ab domain therefore precluding the production of the Ab peptide.26 The 
ADAM10-mediated cleavage of APP protein leads to the production of neuroprotective 
soluble APPα fragment and membrane-embedded fragment CTF83. This CTF83 fragment is 
then further cleaved by the γ-secretase complex. This complex activity produces the P3 
fragment together with the AICD (figure 3).  
 
(Figure 3) Schematic diagram of exclusive APP processing pathways (not drawn in proportion). On left, APP non-
amyloidogenic pathway involving first the major α-secretase ADAM10, cutting APP within Ab domain and producing 
sAPPα fragment and C83, which is cleaved further by g-secretase producing P3 and AICD fragments.  On the right, APP 
Amyloidogenic pathway involves the b-secretase BACE1, cutting APP in N-terminus domain and therefore, producing 
sAPPb and C99 fragement, which is further cleaved by g-secretase producing AICD peptide and Amyloid-b peptide. 
(Scheme credit: A. Ribeiro). 
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The unbalance between those two exclusive pathways is pointed as potential cause of the 
development of the disease.27 Many scientific efforts are focusing on unravelling the 
molecular mechanisms triggering this unbalance yet no tangible elements have been brought 
to light. The unbalance of APP processing and the excessive formation of the Aβ peptide 
could lead to dramatic repercussion on synaptic transmission and therefore cause the deficits 
AD.
 
2. Alzheimer’s disease as synaptopathy 
 
2.1. Synaptic transmission 
 
With an average mass of 1,3 kilogram able to fit in hands, the brain represents the most 
complex system in the universe. Composed of a billion neurons, with each of them forming 
up to 100.000 synaptic connections, there are more synapses in an average human brain than 
stars in the milky way. Those synapses are close but not continuous connection between 
neuronal cells allowing them to exchange information thanks to substile changes in ion 
gradients that drives the release of chemical neurotransmitters.28 This notion of synaptic 
transmission has been proposed as taking place in this tight assembling that consist of a pre-
synaptic part, a synaptic cleft were neurotransmitters are released and a post-synaptic density 
(PSD). The presynaptic active zone is filled with neurotransmitters-filled synaptic vesicles 
ready to fusion with the presynaptic membrane to release in the synaptic cleft (figure 4).29 
The synaptic cleft is a space of 23,8nm width containing a extracellular matrix mainly 
composed of cell adhesion molecules to hold pre and post-synaptic compartment together and 
keep proper distance of separation.30  
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(Figure 4) Image acquired via Electron microscopy. Visualization of a synapse Cross section with dendrite synapsing with 
axon containing synaptic vesicles. The plasma membrane of the pre-synaptic cell is specialized in the release of vesicles. 
These vesicles filled with neurotransmitter, are grouped in these areas as ready to be released. The post-synaptic density 
facing the presynaptic cell, contains receptors that can be activated by neurotransmitter binding. (Credit Image: the 
Okinawa Institute of Science and Technology, website: https://oist-prod-www.s3-ap-northeast-1.amazonaws.com/s3fs-
public/photos/synaptosome.png). 
 
 
The PSD facing the presynaptic active zone appears to be thickened and electron dense. This 
dense post synaptic membrane contains many proteins embedded in the membrane such as 
receptors, adhesion molecules, signaling molecules. This assembly together with all its 
molecular actors are sustaining synaptic transmission. This biological process allows neurons 
to communicates with a target cell across the synapse. Another type of Electrical synapse 
transmission involves the transfer of electrical signals through gap junctions. This type of 
synaptic transmission is found in nerves were fastest response possible is needed as in 
defensive reflexes. In contrary, the chemical synaptic transmission involves the release of a 
neurotransmitter from the pre-synaptic neuron, and neurotransmitter binding to specific post-
synaptic receptors as described above. Chemical synapses are crucial for the biological 
computation supporting basic regulation of body functions but also high cognitive processes. 
It is known that the hippocampus is dependent on glutamate signaling to a greater extent than 
other neocortical tissue, a feature that underlies cognitive functions such as learning and 
memory. 
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2.2. Glutamatergic transmission 
 
The Glutamate system is the principal excitatory neurotransmitter in the CNS.31 The principal 
mediator of this system is the amino acid glutamate that can bind on different glutamate 
receptors (GluRs) such as α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors 
(AMPARs), N-methyl-D-aspartate receptors (NMDARs) and metabotropic Glutamatergic 
receptors (mGluRs), which are specifically targeted and clustered at the PSD.32 Those 
receptors are assembling of proteins complexes tightly associated to regulate signal 
transduction but also membrane removal, local expression and clustering.31 
 
Two major GluRs are known: Ionotropic receptors favorized the positively charged ions flux 
through their pores when activated by glutamate. They serve as ion channels. Metabotropic 
receptors do not conduct ion flux but rather when activated by glutamate trigger intracellular 
cascade via G protein. Thanks to crystallography studies different types of ionotropic 
glutamatergic receptors (iGluR) have been identified: AMPA, NMDA and Kainate rectors 
named after their agonists. After studies using cloning, they have been reported to have 
different functions depending on their subunit composition. The iGluR have four large 
subunits of more than 900 residues. All iGluR have three transmembrane domains (M1, M3 
and M4) and a cytoplasmic membrane loop (M2) with the N-terminus located outside the cell 
and the C-terminus inside the cell. Agonist binding on the iGluR forces a conformational 
change leading to an increase probability of the opening of the ion channel. The different 
glutamate receptors have different affinity. The EC50 (half maximal effective concentration) 
of glutamate at NMDA receptors is approximately 1 μmol/l, while at AMPA receptors it is 
approximately 400 μmol/l.33  
 
The number of surface receptors is regulated by insertion and removal from the membrane 
allowing glutamatergic transmission events to be subject to precise use-dependent changes. 
The two main paradigms by which synaptic plasticity modulate excitatory synapses are the 
Long-Term potentiation (LTP) and Long-Term Depression (LTD). These two paradigms are 
primary models for investigating the synaptic basis of learning and memory in vertebrates.34 
The induction of LTP leads to an increase of the strength of the synapses and is triggered by 
activation of NMDARs. This activation induces the insertion of AMPARs into the 
postsynaptic membrane via a signaling cascade. The induction of LTD leads to a decrease of 
INTRODUCTION 
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synapse efficacy and is mediated by the endocytosis of AMPARs.35 Blocking the activation 
of NMDARs using antagonist DL-2-amino-5-phosphonovalerate (APV) prevents LTP and 
LTD induction in the hippocampus.36/37 
 
 
2.2.1.  AMPA Receptors 
 
AMPA receptors are known to support fast synaptic excitatory transmission. They are 
heterotetrameric as assembles of four subunits in dimer-of-dimers manner (Glua1-Glua4).38 
With predominant Glua1/Glua2 heteromers (comprising for around 80% of all synaptic 
AMPARs) together with Glua2/Glua3.39 The Glua4 subunit being essentially present during 
development and mostly absent in mature adult synaptic neurons.40 The AMPARs can be 
activated by its agonist glutamate and blocked by antagonists such as 6-ciano-7-
nitroquinoxaline-2,3-dione (CNQX) and 2,3- dihydroxy-6-nitro-7-
sulfamoylbenzo(f)quinoxaline (NBQX). The subunits of AMPAR have two splice variants 
occurring in the flip and flop region. They are found at the C-terminal end of the loop 
between third and fourth transmembrane sites. The small change in amino acids composition 
can result in altered desensitization kinetics (Figure-5). 
 The different subunits composing the AMPARs modulate their permeability to Calcium 
(Ca2+), sodium (Na+) and potassium (K+).41 The Glua2 subunit dictating the permeability to 
calcium and thus guarding against excitotoxicity.42 
 
 
(Figure 5) Scheme showing structure of the GluN2A subunit of AMPARs. The subunit is composed of 4 transmembrane 
domains (TMI-TMIV). The C-terminus domain being intracellular and the N-terminus which is the binding domain for 
ligands is extracellular. Splice variation have been identified in the Flip/Flop region, leading to two possible variants for 
each gene sequence. (Representation credit: Bristol University Center for synaptic plasticity, website: 
http://www.bristol.ac.uk/synaptic/receptors/ampar/). 
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GLUA1 and GLUA2 containing AMPA receptors are principally found in the forebrain. The 
modulation of synaptic plasticity and its impact on learning can also be the result of AMPAR 
subunits phosphorylation.  This modulation via phosphorylation can impact general function 
of the AMPARs such as conductance, channel localization and opening probability. 
The GluA1 subunit is mainly present in hippocampal and neocortical neurons.43 Its 
phosphorylation occurs on serine, threonine and tyrosine sites residues on intracellular C-
terminal domain.44 Threonine and Serine being the major residues on which phosphorylation 
occurs.45 Synaptic plasticity studies have shown implication of Ser831 and Ser845 
phosphorylation in LTP and LTD expression.46 Phosphorylation on Ser831 is due to action of 
the PKC and CamKII, while Ser845 is phosphorylated by Protein Kinase A (PKA).47 The 
phosphorylation of Ser831 helps insertion of GluA1-containing AMPAR into the synapse 
while the phosphorylation of Ser845 regulates its opening probability. Those mechanisms of 
phosphorylation can also increase synaptic strength by enhancing channel conductance of the 
AMPARs.48  
 
The GluA2 subunit is essential to confer AMPARs impermeability to Ca2+.49 
Phosphorylation sites have been observed on GluA2 intracellular C-terminal domain. Among 
those, Ser863 and Ser880 are the most common.  PKC Phosphorylation of Ser880 residue has 
been shown to be implicated in synaptic plasticity.50 
 
The GluA3 and GluA4 subunits are strongly present in forebrain structures during adult stage 
in comparison to GluA1 and GluA2 subunits.51 Similar phosphorylation sites implicated in 
synaptic plasticity mechanisms are found on GluA1, GluA2 subunits and on GluA3, GluA4 
subunits. GluA3-containing AMPARs might contribute to synaptic potentiation to form 
hippocampal LTP. This potentiation doesn’t require AMPARs trafficking but instead would 
require an increase of the channel opening probability of GluA3-containing receptors at 
synapse via cAMP activity.52 
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Spontaneous activity has been observed to trigger an increase of GluA4-containing AMPARs 
in the synapse. Their expression is confined to early post-natal development period and is 
specific to pyramidal neurons of the hippocampus. This may have unique plasticity rules 
relevant for synapse maturation. However, GluA4 implication in synaptic plasticity is still 
unclear.53 
 
2.2.2. NMDA Receptors 
NMDA receptors play a critical role in synaptic plasticity and the learning process. 
Functional NMDA receptors are heteromeric, assembled from seven identified subunits to 
date, falling in three different subfamilies: GluN1 subunit , Four GluN2 subunits A–D, and 
two GluN3 subunits A–B (Figure-6).54  
 
(Figure 6) Scheme of NMDA receptor subunits composition. Effect and binding sites location of agonists (Glutamate), co-
agonist (Glycine), inhibitors (Ifenprodil). (Representation credit: Review 2013, Paoletti et al). 
 
The number of residues per subunit ranges from 900 to over 1,480. Each subunit is 
alternatively spliced, making the number of potential NMDA receptor subunit combinations 
very large. Most commonly GluN1 being associated to GluN2 or GluN2 associated with 
GluN3.55 GluN1 is ubiquitously expressed in the CNS from E14 to adulthood.56 The GluN2A 
subunit is responsible for the diversity of composition of NMDARs and is known to have 
drastically 
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different spatiotemporal expression.57 This subunit is fully expressed in all CNS at adult stage 
and inversely GluN2D subunit decrease along the development to be only sparsely expressed 
in low levels in the diencephalon and mesencephalon at adult stage. The GluN2B subunit is 
expressed in high level post-natal and reach a peak around a week old to then lower to be 
restricted to forebrain. The GluN2C subunit expression appears around postnatal day 10 and 
is mainly restricted to the olfactory bulb and the cerebellum. The GluN3A subunit expression 
peaks in early postnatal life and then declines progressively. Conversely, GluN3B expression 
increases throughout development, and is expressed at high levels in motor neurons at adult 
stage. The implication of GluN2B, GluN2D and GluN3A during early development suggest 
important function of these subunits in plasticity.  
Receptors containing GluN1 subunit coupled to different types of GluN2 subunits have been 
described and divided in two categories. The Di-heteromeric NMDARs containing only one 
type of GluN2 subunit (e.g. GluN1/GluN2B or GluN1/GluN2A). And the Tri- heteromeric 
NMDARs containing more than one type of GluN2 subunit (e.g. GluN1/GluN2A/GluN2B) 
that are present importantly in the hippocampus and cortex where they represent from 15% to 
50% of total receptors (figure-7).58 
 
(Figure 7) Scheme representing potential Di- and Tri-heteromeric NMDA receptor composition. Di-heterotrimeric NMDARs 
composed of only one type of GluN2 subunit. Tri-heterotrimeric NMDARs containing more than one type of GluN2A 
subunit. (Representation credit: Review 2013, Paoletti et al). 
NMDARs are cationic channels permeable to sodium (Na+), potassium (K+) and calcium 
(Ca2+) ions. In particular, Ca2+ influx is the critical factor mediating many of the NMDAR-
specific physiological and pathological events. Characteristically all NMDARs are voltage 
dependent-Mg2+ blocked and are permeable to Ca2+ conferring them slow kinetic type of 
responses. Glutamate binding but also a co-agonist such as Glycine or D-serine is needed for 
them to be activated. They have also modulatory sites that confer them a fine sensibility to 
their environment. Those binding sites act as positive or negative allosteric modulators in 
response to numerous substance such as protons, polyamine and Zinc.59 NMDARs are 
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expressed on astrocytes and have been observed in peri- and pre-synaptic site in the CNS.60 
However they are mainly expressed on the post synaptic site of the synapse.61 
 
2.2.3. Metabotropic Glutamate Receptors 
 
Glutamate acts not only ionotropic channels but also on metabotropic receptors and their 
signaling pathways. Metabotropic glutamate receptors (mGlus) comes in eight subtypes 
mGlu1-mGlu8. Among them seven are express in the CNS exerting neuromodulatory role. 
They have been categorized in three functional classes considering their amino-acid sequence 
homology, their agonist pharmacology and the signal transduction pathways they are 
associated with. The following categorization in currently accepted and used by the scientific 
community: Group I (mGluR1 and mGluR5), Group II (mGluR2 and mGluR3), and Group 
III (mGluR4, mGluR6, mGluR7, and mGluR8)). All mGluRs are G protein-coupled receptors 
(CGRPs) therefore, link to G trimeric cytoplasmic enzymes that can activate a wide range of 
intracellular signaling pathways. Protein G activation is dependent on a disulfide bridge 
between cysteine residues in the extracellular loop and the third transmembrane domain. 
Most of these identified receptors display a large extracellular domain essential for ligand 
recognition. This extracellular domain called a Venus Flytrap module is structurally similar 
to bacterial periplasmic proteins involved in the transport of small molecules (Figure-8).62 
The classification of mGlu receptors into three groups is further supported by a consideration 
of their signal transduction mechanisms.  
G protein-coupled receptors Group I includes mGluR1 and mGluR5, that are coupled to Gq-
proteins activating Phospholipase C (PLC) to produce inositol 1,4,5-trisphosphate (IP3). 
Signaling molecule, IP3 is known to trigger opening of Ca2+ channels in the endoplasmic 
reticulum increasing in this way the intracellular calcium concentrations. Activation of 
phospholipase C leads not only to the formation of IP3 but also diacylglycerol (DAG). DAG 
remains in the membrane as a co-factor for PKC activation. Splice variants have been 
described for both mGlu1 and mGlu5. The main mGluR1 variants are 1b and 1d, for which 
the last 318 C-terminal amino acid residues of the original mGluR1a variant are replaced by 
20 and 26 (22 in human) residues in 1b and 1d, respectively.63 For mGlu5R, the 5b variant 
differs from the first identified 5a receptor by the insertion of a cassette of 32 amino acid 
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residues 49 residues after the 7TM.64 Agonist 3,5-dihydroxyphenylglycine (DHPG) is 
specifically selective for group I.65 
  
(Figure 8) Scheme of the mGluR dimer in different activity states. mGluR dimers contain two large extracellular domains 
called Venus flytrap domains (VFDs), which bind glutamate and other orthosteric ligands. The cysteine-rich domain links 
the VFDs to seven transmembrane-spanning domains. The intracellular C-terminal domain is subject to alternative splicing 
leading to generation of different C-terminal protein tails. The open-open state (left) is the inactive state and can be 
stabilized by different antagonists. Either one or two VFDs can then bind glutamate, resulting in active receptor 
conformations. (Representation credit: Niswender Cm, Conn PJ. 2010. Annu. Rev. Pharmacol. Toxicol. 50 :295-322.). 
 
G protein-coupled receptors Group II includes mGluR2 and mGluR3 that are coupled to Gi-
proteins and are able to inhibit the adenylyl cyclase activity and different types of Ca2+ 
channels. Agonist 2R,4R-4-aminopyrrolidine- 2–4-dicarboxylate (APDC) is strongly 
selective and mildly potent (400 nmol/l) for G protein-coupled receptors group II. G protein-
coupled receptors Group III includes the four others mGluR (4,6,7,8) and are coupled to Gi/o 
proteins. Like group II, mGluRs group III are able to inhibit the adenylyl cyclase activity 
together with Ca2+ and K+ channels activity. Agonist l-amino-4-phosphonobutyrate (l-AP4) 
is selective of group III mGluRs. 
An important number of ligand-gated Na+ and K+ channels are also modulated by mGlu 
receptor activation including NMDA and kainate receptors. Activation of mGlu receptors acts 
to inhibit or potentiate ionotropic receptor depending on the signal transduction mechanism. 
Action of mGlu receptors can be excitatory by increasing conductance and therefore the 
release of glutamate from the presynaptic cell. Or else their activation can inhibits the release 
of glutamate and therefore modulate voltage-dependent calcium channels.62 In hippocampal 
pyramidal cells, group I mGlu receptor activation potentiates currents through NMDA 
receptors activity. This effect is reduced by inhibitors of either protein kinase C or Src 
tyrosine kinase, and may proceed through dual signaling pathways.
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2.3. Dysfunction of the synapse 
 
The synaptic transmission is highly efficient but a fragile mechanism. Dendritic spines go 
through activity-dependent morphological and density changes allowing the structural 
plasticity of the spines to be closely modulated by synaptic function. Studies observed that an 
enlargement of the spines accompanies LTP. In contrary, LTD was observed to be associated 
with a shrinkage of the dendritic spines. These subtle morphological changes affect 
connectivity in neuronal circuits and the overall synaptic function.66 Because synaptic 
transmission is the base for cognitive processes such as memory. The morphology and 
density of synapse have been studied has a potential driving force for AD. Extensive 
postmortem pathological studies of AD patients showed a low level of spines density 
throughout the cortex and hippocampus of affected brains.67 Interestingly, a stronger 
correlation has been observed between cognitive decline and synapse/dendrite loss rather 
than to neuronal loss or neurofibrillary tangles. This synaptic loss could appear early in AD 
as it has been observed in Mild cognitive impairment (MCI) and has been also observed in 
greater extent in AD. Indicating that AD synaptic loss could worsen together along the 
cognitive deficit.68 Moreover, the synaptic loss has been observed to be higher than expected 
in regard of the neuronal loss. This underlying synaptic defects as an important pathological 
mechanism of AD thereby, as a strong drive for the cognitive deficits rather than a exclusive 
consequence of neuronal death.69 Some studies interestingly observed synaptic compensatory 
mechanisms in AD such as an increase of the size of the remaining dendritic spines. Further 
investigation of these compensatory mechanisms is important as representing future potential 
disease modifying strategies. 
The overproduction of the Aβ peptide in AD is known to impact negatively synaptic 
transmission in the absence of significant neurodegeneration. Human Aβ can exist in diverse 
species as its process of aggregation goes on. These different species of Aβ include 
monomers, dimers, trimers, tetramers, dodecamers and after further aggregation protofibrils 
that can lead to mature fibrils. These mature fibrils can ultimately form amyloid plaques in 
brain tissues. These Amyloid plaques created by aggregation of small peptides of not more 
than 50 amino acids are finally of detectable size via microscopy.70 The soluble Amyloid-β 
forms are the perfect candidates that could first trigger synaptic dysfunctions prior to the 
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heavily network disruptions caused by neurotoxic Amyloid plaques load. Studies show, that 
soluble species of Amyloid-β produced at early stage of the pathology are implicated in 
synaptic failure.71 Small soluble Amyloid-β oligomers were observed to alter synaptic 
plasticity as leading to rapid inhibition of long term potentiation.72 That effect on synapses 
precede neuronal death and leads first to synaptic failure causing the memory loss. The 
association of Amyloid-β peptide with memory impairment started from a study on 
transgenic mice Tg2576 which express human APP695 containing the Swedish mutation 
(K670N/M671L).73 These transgenic mice have high levels of Aβ1–42 in the brain and display 
cognitive deficits when performing spatial memory task.74 Also, a correlation between 
severity of the cognitive deficits and spine density has been shown in many other studies. 
Furthermore, a decrease in synaptic density is observed in hippocampus of AD patients.75 
This decrease is synaptic density is disproportionate to the actual loss of neurons supporting 
again the fact that synaptic failure precede neuronal loss.76 Moreover, several 
electrophysiological studies observed a significant synaptic deficit in human APP transgenic 
mice well before the development of Amyloid-β deposits detectable via microscope.77 The 
post synaptic compartment of excitatory synapse could be the early target 
of Amyloid-β as it has been observed to bind PSD-95-containing post synaptic sites.78 
Together with post synaptic density complexes containing NMDA receptors.79 Experiments 
also showed that Amyloid-β induces a reduction of PSD95 levels in a time- and dose-
dependent manner.80 Furthermore, NMDAR internalization occurs via high affinity binding 
of the Amyloid-β1-42 to the a7-nicotinic acetylcholine receptor. The binding of Amyloid-β1-42 
enhanced the a7-mediated Ca2+ influx and activation of the serine-threonine protein 
phosphatase 2B, a Ca2+ sensitive enzyme that regulates NMDA transmission and synaptic 
plasticity. PP2B action dephosphorylate and activates striatal-enriched tyrosine phosphatase, 
which will dephosphorylate the NMDA receptors subunit NR2B on tyr1472. This 
dephosphorylation result in the internalization of NR2B containing NMDAR.81 Amyloid-β 
has undoubtedly many effect on the synaptic plasticity. 
 
Amyloid-β negatively impact number of postsynaptic NMDAR creating an unbalance of 
activity between synaptic and extrasynaptic NMDAR. Applied Amyloid-β also enhances 
NMDAR endocytosis and decrease synaptic expression of cultured cortical neurons.81 In 
accord with these finding the calcium influx after NMDA activation via glutamate uncaging 
at single spines is significantly altered after treatment with Amyloid-β.82 Hippocampal slices 
treated with Amyloid-β containing media show reduced expression of PSD-95 and NR2B in 
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synaptic but not extrasynaptic fraction.83 In the same manner, Amyloid-β peptide in 
hippocampal cultures has been observed to decrease synaptic currents from glutamatergic 
neurons.84 Together these results reveal that Aβ specifically triggers NMDAR internalization 
of at the synapse but not in extra synaptic. However, it is well known that Aβ promotes tonic 
glutamate build up in the extracellular space therefore activating extrasynaptic NMDARs. 
Reduction in Glutamate transporters expression is observed in tissue from AD patients.85 
Studies have also observed in hippocampal neurons an enhancement of presynaptic glutamate 
release, an inhibition of glutamate uptake, and a general increase in extracellular glutamate 
concentration provoked by  Aβ application.86 It was also recently shown to reduce the 
expression of glial glutamate transporter GLT-1.87 When using MK-801 to preblock synaptic 
NMDAR, Aβ from brain extract, cell culture or synthetic Aβ have been observed to still 
induce NMDA dependent current.84 Using Ro25-6981 this effect is blocked suggesting that 
Aβ leads to increased activation of NR2B-containing NMDAR extrasynaptic. Adding to the 
reduction of glutamate uptake, Aβ can also provoke extrasynaptic NMDAR activation by 
glutamate release from glia cells. Whole cell current from cultured microglia demonstrated 
that the outward current composed of glutamate and sodium in response to potassium 
stimulation are significantly higher in cultures treated with Aβ.88 Furthermore, Aβ was also 
observed to directly impact glutamate release from glia cells, thus increasing the probability 
of activation of extra-synaptic NMDAR. 
 
Synaptic transmission together with exocytosis dictates the extracellular release of Aβ.89 Bath 
application of NMDA to cultured cortical neurons leads to a shift in a-secretase to β-
secretase processing of APP, increasing the production and release of Aβ and reducing 
sAPPa levels. This effect via NMDA application was underlined by upregulating expression 
of APP containing kunits protease inhibitor domain.90 Synaptic NMDA activity increase 
alpha-secretase mediated processing of APP.91 In contrary, extrasynaptic NMDA mediated 
production of Aβ creates a vicious circle of toxicity in which Aβ promotes extrasynaptic 
NMDAR activity, which lead to further production and secretion of the peptide. Many 
signaling pathways are implicated in these extrasynaptic NMDAR mecanisms and AD 
synaptic disfunctions. CREB mediated gene expression is implicated in cell survival together 
with synaptic plasticity as well as memory. Interestingly decreased levels of phosphorylation 
of CREB serine-133 was observed in AD patients.92 This decreased was also observed after 
extrasynaptic NMDAR stimulation.93 Using treatment to increase cAMP signaling pathways 
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such as rolipram and forskolin reverts CREB phosphorylation together with the synapse loss 
and LTP deficits observed in AD.94 Aβ treatment translocates Jacob to the nucleus in the non-
phosphorylated form.95 After synaptic NMDAR stimulation Phosphorylation of Jacob is 
associated BDNF, CREB and Arc signaling as neuroprotection.96 At contrary the non-
phosphorylated form of Jacob is transported directly after excitation of the extra-synaptic 
NMDAR. This effect on Jacob lead to a decrease of the activity of CREB, a decrease of the 
complexity of dendritic ramifications and a decrease in synaptic density. Moreover this effect 
on Jacob is blocked by the NR2B-specific antagonist ifenprodil, demonstrating that Jacob 
translocation induced by Aβ is dependent on NR2B-containing NMDAR.97 BDNF can 
promote Serine-133 CREB phosphorylation through CamKIV or ERK1/2 activation, 
furthermore the BDNF gene is a CREB target.98 BDNF levels decreases with CREB activity 
levels in the brain, serum and CSF of AD mouse models.99 Interestingly this was also 
observed in of AD patients.100 Moreover BDNF induction is blocked by extrasynaptic 
NMDAR activity.93 Supporting the use of stem cell as therapeutic against neurodegenerative 
diseases, studies mouse model of AD showed that stem cell implantation can restore 
cognitive deficits. Very interestingly this cognitive improvement was independent to Aβ and 
role of BDNF downstream Aβ and/or tau pathogenic effects.101 In the same fashion, 
improvements of cognitive deficits via BDNF increase in transgenic mice ,was also achieved 
via viral delivery of CREB binding protein independently to tau or Aβ pathology.102 These 
results show that tau or Aβ pathology rely in some extent on negative effects of CREB and 
BDNF signaling. 
 
High numbers of studies have shown that Aβ can impair NMDA dependent LTP at 
hippocampal CA1 synaptic plasticity in AD.103 This deficit in synaptic plasticity could be due 
to overstimulation of extrasynaptic NMDAR. Aβ-induced LTP inhibition can be prevented 
by decreasing extrasynaptic glutamate levels. Inhibition of calpain or p38MAPK was also 
observed to prevent the LTP impairment. Aβ wide impact on synaptic transmission 
mechanisms could lead to dramatic events. To some extent the aggregation of the peptide 
could also lead to phosphatase dysfunctions provoking the scrambling down of cell’s 
cytoskeleton caused by tau hyperphosphorylation and ultimately followed by neuronal death. 
Among those pathological mechanisms, Amyloid-β could also interferer with the 
physiological function of receptors, signaling pathways and general maintenance of the cells 
responsible for affecting the synaptic transmission, leading to disruption in information and 
cognition. 
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3. The alpha secretase ADAM10  
 
3.1. ADAM10 as member of the synapse 
 
 
Members of the “A Desintegrin and Metalloproteases” (ADAM) family are composed of 
inactive and active proteases such as ADAM9 and ADAM17. Among them, ADAM10 is a 
type 1 membrane glycoprotein composed of 748 amino acids. It is implicated in many 
important processes in the CNS such as synaptic plasticity, neurodevelopment and regulation 
of spine morphology. ADAM10 is membrane-anchored protease that has for role to cleave 
ectodomain of transmembrane or simply membrane bound proteins. Over ten years ago, it has 
been described as the major alpha secretase acting on the Amyloid precursor protein (APP). 
Because of this, interest kept growing since ADAM10 could represent a new therapeutic 
target in AD. ADAM10 is found inactive in the Golgi as the proenzyme needs a post-
processing to be functional. After removal of the signal sequence, the inactive form of the 
sheddase is translocated to the secretory pathway where its activated by the proprotein furin 
or PC7 (Figure-9).104 The Furin cleavage of ADAM10 takes place basic amino acid 
sequences R-X-K/R-R and R-X-X-R of the C-terminus domain.  
 
 
(Figure 9) Furin cleavage within the Golgi removes ADAM10 prodomain and leads to the mature and fully active form of 
the sheddase. ADAM10-mediated ectodomain shedding of substrates triggers intra-membrane proteolysis by g-secretase 
or by signal peptide peptidase-like proteases (SPPLs).105 (Representation credit: Review 2015, Lichtenthaler et al).  
 
The furin endoprotease acting in the secretory pathway is present mainly in the Trans Golgi 
Network (TGN), however it can be found also in clathrin-coated vesicles, on the plasma 
membrane and in the cytosol of the cell.106  
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By coexpressing a prodomain-deleted ADAM10 mutant together with its prodomain in trans, 
ADAM10 prodomain was shown to exhibit a dual function: The prodomain can inactivate 
endogenous ADAM10 in cell culture conditions while overexpressing ADAM10 lacking its 
prodomain was observed to be inactive. At contrary, the prodomain co-expressed in trans 
restors the proteases role of ADAM10 mutant lacking intracellular prodomain.104  In further 
in vitro experiments, application of purified prodomain was observed to inhibits potently and 
selectively the enzyme.107 Put together, these data show that ADAM10 prodomain acts 
transiently as an inhibitor and also as a modulator of the enzyme maturation. Mutation of 
ADAM10 active site zinc-binding motif leads to a decrease production of sAPPα fragment.108  
Although the deletion of ADAM10 disintegrin domain was shown to not affect strongly the 
shedding of APP protein in cell cultures, the processing of some other substrates of ADAM10 
is supposedly thought to be impacted also by non-active sites.109 Supporting experiments 
using cells knockout for ADAM10 that were overexpressing a mutant of ADAM10 lacking 
the cytoplasmic domain showed a partial impairment of epidermal growth factor cleavage.110 
Translocation of ADAM10 through the secretory pathway leads to its active protease form. 
ADAM10 was observed to display proteolysis activity in secretory pathway and mainly at the 
cellular membrane. Experiments using cell surface biotinylation showed that most active 
ADAM10 is found embedded in the plasma menbrane.111  
Apart from APP, ADAM10 has numerous substrates among the most important:  Prion 
protein (PrP), neuronal (N)-cadherin, ephrins, Notch and many others reaching at least a total 
number of 40 substrates.112 PrP processing involves ADAM10 and ADAM17 mediated 
cleavage. An increase of ADAM10 and ADAM17 activity could represent a therapeutic 
strategy as increased shedding of PrP could reduce its toxic effect. 113 N-cadherin cleavage by 
ADAM10 downregulates neuronal cell adhesion. Moreover, further N-cadherin shedding at 
plasma membrane is realized by γ-secretase. Cleavage of N-cadherin by γ-secretase releases 
its adaptor protein β-catenin promoting the induction of β-catenin target genes. Shedding by 
ADAM10, therefore, turns the adhesive function of N-cadherin at the cell surface into a 
signaling function which is critical for N-cadherin mediated induction of gene expression.114 
ADAM10 can cleave ephrin A5 bound to EphA3 and thus terminate binding via ephrin. 
Notably, the ephrin receptor EphB2 also undergoes calcium-influx and n-methyl-d-aspartate 
(NMDA)-induced cleavage that is sensitive to ADAM10 inhibition. Thus, by cleavage of 
ephrins as well as their receptors, ADAM10 can be regarded as promoter of axon guidance 
and extension in the CNS.115 
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The receptor Notch and its ligand Delta 1 take part in many neurogenesis-related functions as 
implicated in embryogenesis via neuroepithelial development, but also in neuronal stem cell 
sustainment and their self-renewal in the adult CNS. Both sheddase ADAM10 and ADAM17 
cleave Notch extracellular domain. The remaining cell-associated Notch is then directly 
followed by γ-secretase intramembranous cleavage. This results in the generation of a 
cytoplasmic cleavage fragment which can translocate into the nucleus and function as 
transcription factor. Thus, ADAM10 and potentially ADAM17 are critically involved in the 
transcriptional signaling pathway of Notch and are required for its functions in neurogenesis 
even in the adult CNS.116  
 
Through its action towards APP and its other substrates, ADAM10 is implicated in many 
molecular mechanisms responsible for the formation, maturation and stabilization of 
dendritic spines.117 It’s an important and dynamic actor of the of PSD as sensitive to changes 
in synaptic plasticity. Changes in synaptic activity strength affects its interaction with binding 
partners and modulate synaptic localization. As in the case of glutamate receptors, ADAM10 
insertion in the synaptic membrane is controlled by LTP and LTD. 118 
 
3.2. Trafficking of ADAM10 
 
Regulation of ADAM10 activity is mediated at different levels, i.e. modulation of promoter 
activity, the degree of prodomain release, cellular trafficking, cellular signaling and lipid and 
protein interactions. ADAM10 activity in neurons is first of all modulated by its intracellular 
trafficking. The interaction with the synapse-associated protein 97 (SAP97), which modulate 
the trafficking of glutamate receptors, has been observed to directly bind ADAM10 and 
positively influence the sheddase’s activity.118  
 
The SH3 domain (PPPKPLP) of SAP97 binds to the proline-rich domain of the cytoplasmic 
tail of ADAM10, therefore driving the insertion of the sheddase in the postsynaptic 
membrane, in fine increasing α-secretase activity. This mechanism was observed to be 
promoted by short-term NMDA receptors activation during in vitro experiments on primary 
neurons.119 NMDAR activation can also trigger an increase expression of genes encoding for 
ADAM10 and β-catenin proteins. This upregulation of ADAM10 was blocked using 
inhibitors of Wnt/β-catenin signaling pathway. On the other hand, the activation of the 
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Wnt/β-catenin signaling pathway has been observed to increase ADAM10 expression. 
Furthermore, ERK inhibitors blocked both the NMDAR and Wnt3A-mediated increase 
expression of ADAM10. All these observations point to a control of ADAM10 expression by 
the NMDAR via the Wnt/MAPK signaling pathway.120 
 
ADAM10 C-terminal was shown to contain a motif for Endoplasmic Reticulum (ER) 
retention. Deletion by mutagenesis of a sequence rich in arginine (723 RRR) of this motif was 
leading to the confinement of ADAM10 in the ER.121 ADAM10 internalization is mediated 
by clathrin-mediated endocytosis. The clathrin adaptor 2 (AP2), a heterotetrametric complex, 
bind to the sheddase C-terminal and initiates the internalization.122 
 
(Figure 10) SAP97 and AP2 binding site on ADAM10 cytoplasmic tail. Promoting membrane insertion, SAP97 binds prolin 
rich domain of ADAM10 cytoplasmic tail. Promoting chlatrin-mediated endocytosis, AP2 binds RQR sequence of ADAM10 
cytoplasmic tail. This sequence is composed of 2 positively charged residues, R735 and R737, and a hydrophilic amino acid, 
Q736. The two R residues have been observed to be crucial for the binding. (Representation credit: Review 2017, Marcello 
and Musardo).  
Using different experimental methodology, the details of ADAM10/AP2 association have 
been characterized. An AP2-binding sequence (RQR) has been identified on the cytoplasmic 
tail of ADAM10. This sequence is essential for AP2 binding on ADAM10 and therefore for 
its internalization.118 
Studies have shown, that ADAM10 synaptic availability is significantly affected by its 
internalization with AP2. This demonstrating the relevance of clathrin-dependent 
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internalization in the regulation of ADAM10 cell surface expression. Furthermore, both 
SAP97 and AP2 directly bind the Cytoplasmic domain of the sheddase in a non-overlapping 
fashion (Figure-10).  
Thus, synaptic plasticity has been observed to affect the binding of SAP97 or AP2 on 
ADAM10. In particular, LTD was found to upregulate the sheddase insertion in the plasma 
membrane as promoting its SAP97-dependent forward trafficking. On the contrary, LTP was 
found to reduce the synaptic availability of the sheddase by promoting AP2 clathrin-mediated 
endocytosis.118 
 
3.3. ADAM10 in AD 
 
 
The alpha-secretase role is deeply intricated in synaptic physiology and also observed to be 
modulated in an activity-dependent manner by synaptic activity. ADAM10 has many further 
functions through the cleavage of its substrates such as promoting hippocampal neurogenesis, 
the homeostasis of neuronal networks and axonal guidance. AD pathological mechanisms act 
on neurons by first degradation the synaptic transmission.26 Evidences show that synaptic 
dysfunction plays a central role in AD, since it drives the cognitive decline and it is not just a 
consequence of cell death.69 AD patients, cognitive decline has a stronger correlation to 
synapse loss rather than to neurofibrillary tangles or neuronal loss.67 The production of the 
Aβ oligomer act on synaptic transmission leading to dysfunction of the synapse. Indeed, 
pathological Aβ levels and Aβ oligomers may indirectly cause a partial block of NMDA 
receptors and shift the activation of NMDA receptors-dependent signaling cascades toward 
pathways involved in the induction of LTD and synaptic loss.82 This effect on NMDAR and 
synaptic transmission would affect ADAM10 well function through diverse mechanisms.  
 
Recent studies, showed that ADAM10 trafficking mechanism and ADAM10/SAP97 
association are involved in AD pathogenesis. Interestingly, ADAM10 synaptic levels and 
ADAM10/SAP97 association are reduced in the hippocampus of AD patients at an early 
stage of disease.123 Furthermore, interfering with the ADAM10/SAP97 complex for 2 weeks 
by means of a cell-permeable peptide strategy in mice is sufficient to increase amyloid levels 
and leads to the reproduction of initial phases of sporadic AD.124 Together with the 
exocytosis, ADAM10 internalization triggered by ADAM10/AP2 association has also 
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pathological relevance. In fact parallel to a defect in ADAM10 binding to SAP97 a 
concomitant increase in ADAM10 association to AP2 in the hippocampus of AD patients has 
been reported.123 Results suggest that in early stages of the disease, the reduction of α-
secretase synaptic localization and activity is due to a defect in ADAM10 
exocytosis/endocytosis processes rather than to an alteration of its expression.118 
 
Regulation of the interaction between the sheddase ADAM10 and its binding partners SAP97 
and AP2, represents a clear physiological mechanism by which the activity of ADAM10 at 
the synapses can be modulated. This potential action on the sheddase could upregulate 
ADAM10 synaptic levels and thereby, its activity at the synapse. The balance between these 
two partners association is impaired in AD patient’s hippocampus at early stages of disease, 
leading to a reduction of ADAM10 levels at the postsynaptic compartment.123 This loss could 
affect also activity-dependent synaptic plasticity in AD. In light of the role of ADAM10 in 
Aβ production and synapse function, this loss of balance could affect both APP processing 
and lead to formation of a downward spiral towards production of more Aβ leading to more 
unbalance. In this frame 2 mutations have been identified as leading to attenuation of a-
secretase activity and shifting APP processing towards β-secretase mediated cleavage 
increasing Aβ plaque load. On the contrary, ADAM10 expression has been shown to 
potentiates hippocampal neurogenesis.125 All those indicators lead to ADAM10 as having 
major implications in AD synaptic pathology. Among those implications, ADAM10 activity 
on N-cadherin at synaptic sites could contribute to spine remodeling and 
availability/stabilization of active iGluRs. Inhibition of ADAM10 activity on N-cadherin 
induced a significant increase in size of dendritic spines and a modification of the number 
and the currents of synaptic AMPA receptors. In this perspective, ADAM10 represents a 
clear new therapeutical target. 
 
 
4. Drug development 
 
4.1. Available therapeutics 
 
AD drug development has been very active during the last decade, with at least 25 amyloid 
related drugs tested. This intense research effort has not yet provided with a real cure for the 
disease nevertheless research efforts have already produced effective drugs capable of 
improving symptoms. Among currently available drugs for treatment of the pathology are 
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acetylcholinesterase inhibitors.  Early research has shown that the process of 
neurodegeneration in AD affects the basal forebrain by decreasing the number of cholinergic 
neurons and the synthese of acetylcholine.126 Since the cholinergic system was known to be 
implicated in cognitive processes such as learning and memory, a strategy to increase the 
cholinergic transmission was developed. This strategy using Cholinesterase Inhibitors (CI) 
slow down the rate by which acetylcholine present in the synaptic cleft is degraded. Three 
FDA-approved CIs are currently on the market to treat patients suffering from mild to 
moderate AD: Donepezil (Pfizer, New York, USA), Rivastigmine (Novartis, Basel, 
Switzerland) and Galantamine (Janssen Pharmaceutica, Beerse, Belgium).127 CI drugs are the 
standard treatment first administrated to AD patients, however they are not disease modifying 
agents. After later research, a N-methyl d-aspartate receptor antagonist was developed as new 
treatment option for moderate to severe AD. The drug named memantine (Lundbeck, Valby, 
Denmark) acts as an uncompetitive NMDAR antagonist with moderate affinity. This 
compound protects neurons against excitotoxicity.128 Clinical trial studies of 6 months 
treating with memantine have shown improvement of cognitive functions and overall 
behaviors in patients suffering from moderate to severe AD. Supporting these results, a 
review of six randomize controlled trial showed that NMDAR antagonist memantine can help 
decrease the psychological and cognitive symptoms of the pathology. The most frequent side 
effect observed in memantine trials were dizziness, headache and confusion. This compound 
is also known to potentially develop agitation in a small group of patients.129 In most cases, a 
combination therapy of CIs and Memantine is prescribed to help patients. Randomized 
Clinical Trial studies on patients suffering from moderate to severe AD demonstrated a 
significant improvement of the cognitive function of the patients when treated with a 
combination of memantine and donepezil compared to a group treated with memantine and 
placebo.130 Unfortunately no improvement was observed in patients suffering from mild to of 
therapeutics contribute minimal impact on the disease and target late aspects of the disease. 
They slow the evolution of the pathology and provide symptomatic relief but fail to achieve a 
definite cure that would stop the progression.131  
 
 
4.2. Current Clinical trials 
 
Drugs targeting different actors of the pathology are still under extensive research with some 
of them already reaching clinical trials. Currently in the AD treatment pipeline, there are 112 
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compounds being tested. Phase III counts 26 compounds that are in 35 different trials. Phase 
II counts 63 compounds in 75 different trials. Phase I counts 23 compounds in 25 different 
trials. Among agents in phase III clinical trials, 65% are disease-modifying strategies 
addressing amyloid, tau or using other mechanisms of action (MOAs), 4% are cognitive 
enhancers acting as acetylcholinesterase inhibitors, and 31% are compounds addressing the 
neuropsychiatric and behavioral symptoms such as agitation and apathy (figure-11). 131 
 
(Figure 11) percentage representation of the different mechanisms of actions of agents currently in development phase III. 
65% of those agents are disease modifying therapies. Among these drugs 8% focus on neuroprotection and metabolic 
issues, 4% are ant-tau based on anti-aggregation mechanism of action, 54% are considered as anti-amyloid using 
immunotherapy, anti-aggregation as mechanisms of action, also BACE inhibitors. The rest is composed at 31% of 
neuropsychiatric agents focusing on symptoms such as agitation, sleep disorders or apathy. Last 4% are cognitive 
enhancers acting as acetylcholinesterase inhibitors to improve symptoms. (Scheme credit: Zhong et al, 2018) 
 
Disease modifying compound represents most of the research efforts now as strong the need 
for such a drug able to stop the disease increases by the day. Those treatment targets the main 
elements of the disease trying to block or counteract the pathological mechanisms. 
Several compounds that could inhibits the activity of the γ-secretase in the brain have been 
developed. Such strategy could reduce the activity of the sheddase and therefore decrease the 
Aβ production. However, γ-secretase has many essential biological roles through its action on 
its substrates such as the signaling protein Notch known to be implicated in the proliferation 
and differentiation of progenitor cells. Experimentation on transgenic mice demonstrated that 
inhibitors of the γ-secretase at sufficient doses to decrease Aβ production prevented the 
differentiation of lymphocytes representing a clear safety issue for this type of agent.132  
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Scientific research on agents able to block the β-secretase enzyme (BACE) are also in the 
preclinical development phase. Derivative compounds from 11 N-phenyl-1-arylamide, N-
phenylbenzenesulfonamide were developed and experimentally tested for their β-secretase 
inhibitory activities.133 Neocorylin compound with a potential β-secretase inhibitory effect 
was recently isolated from extract of Psoralea corylifolia L. (Fabaceae). In vitro this agent 
exhibits significant inhibitory effects on purified baculovirus-expressed BACE-1 in a dose-
dependent manner.134 In large Randomized clinical trials inhibitors of BACE1 blocked dose-
dependently the formation of Aβ peptide in CSF of AD patients. However, these agents did 
not show any improvement in terms of cognition and psychology of the patients. BACE 
inhibition may be not sufficient to decrease brain Aβ plaques in advanced stage of the 
disease. Evidences suggest that the optimal timing for treatment with BACE1 inhibitors 
should be before appearance of the first cognitive symptoms. The limitation of such 
preventive treatment still represents a crucial issue.135 finally, the location of BACE1 in the 
brain and in the lumen of endosomes makes the development of effective BACE1 inhibitors 
challenging as inhibitors need to cross the blood-brain barrier and neuronal membranes to 
access the target. 
 
Immunotherapy targeting tau proteins or amyloid plaques are extensively studied. 
Approaches using vaccination against tau is considered complicated because of the 
intracellular localization of tau protein. Regarding plaque load the promising antibody 
Gantenerumab, developed by Chugai Pharmaceuticals and Hoffmann-La Roche, is being 
investigated in two Phase III studies to assess the safety and efficacy of subcutaneous 
administration for the treatment of early AD patients. This IgG1 monoclonal antibody 
designed to bind to aggregated forms of Aβ has been previously demonstrated to lower 
amyloid plaque levels in AD patients. The ongoing clinical trial is enrolling more than 1,500 
patients in more than 30 countries worldwide and represents the only anti-amyloid program 
being developed with subcutaneous administration. The possibility to use this route of 
administration could enable home administration for patients affected by this disease. The 
promising data readout of this anti-amyloid clinical trial is expected in 2022. 
 
Recently drug starting to target the alpha-secretase have been also studied. French company 
ExonHit therapeutics recently developed Etazolate (EHT 0202, ExonHit Therapeutics) that is 
described as an enhancer of the α-secretase activity pathway and via its action on the non-
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amyloidogenic pathway inhibits Aβ-induced neuronal death, thus leading to symptomatic and 
effect.  
4.3. The hope for future drugs 
 
Increasing evidence points towards the major alpha-secretase ADAM10 as a good therapeutic 
target for development of future drugs. The sheddase is known to reduce the generation of Aβ 
but may also affect the AD pathology through potential mechanisms including maintaining 
normal synaptic functions, promoting hippocampal neurogenesis and the maintaining 
homeostasis of neuronal networks. The sheddase ADAM10 modulates these functions by 
processing its brain substrates such as postsynaptic cell receptors and adhesion molecules. In 
light of these considerations a new agent has been developed.  
 
The drug Etazolate known as compound EHT0202 (exon hit therapeutics, Paris, France) is an 
alpha secretase potentiator that stimulates the a-secretase neurotrophic activity in the non-
amyloidogenic pathway and inhibits β-secretase related neuronal death. In vitro, the 
compound is neuroprotective against toxic Aβ42 as associated with sAPPα induction effect. 
After a phase I study in healthy volunteers, a phase II clinical trial has been recently 
completed. This clinical trial assessed safety, tolerability and preliminary efficacy on 
cognition and behaviour in AD patients, as well as quantification of sAPPα in blood.136 
Etazolate clinical trial, conducted in 159 patients with mild to moderate AD pathology, was 
observed to be safe and well tolerated by the patients. Now trying to test the peptide on a 
longer period of time and on a larger cohort of patients to confirm its efficacy and 
tolerability. A reduction of the symptoms of 30% was observed in patients treated with the 
drug compared to placebo.137  
 
 
This promising compound that could have both symptomatic effect and disease modifying 
effect by increasing the production of the alpha-secretase together as well as modulating 
GABA-A receptor and PDE-4 inhibitor could represent a way to fight AD. In this frame, our 
study tries to develop an alpha secretase enhancer based on ADAM10 local trafficking in AD 
patients. 
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AD is still representing a major burden for society. In Europe the cost per year of dementia is 
in fact estimated to account for 105 billion euros. These numbers are set to growth due to the 
increase in life expectancy, thus bringing the problem to the level of unsustainability. 
Therefore, finding a cure for AD represents an imperative for modern medicine.  
 
 
 
(Figure 12) The cost of dementia reaches an estimated 105 billion euros in Europe. (Representation credit: DiLuca and 
Olesen, Neuron 2014). 
 
This thesis challenged the hypotheses that ADAM10 trafficking at the synapse is a relevant 
therapeutic target in AD. The increase of the ADAM10 activity could (I) counteract the 
action of BACE thus reducing Aβ formation (II) increase the production of the 
neuroprotective sAPPα fragment. In light of these considerations, the main goal was to 
stabilize ADAM10 levels and activity at the synaptic membrane by disrupting ADAM10/AP2 
complex, thereby interfering with the internalization process of the sheddase. To this, we 
made use of cell permeable peptides already validated in the lab able to disrupt 
ADAM10/AP2 complex.  
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These cell permeable peptides are composed of a TAT sequence and of the sequence 
responsible for AP2/ADAM10 association (Figure 13). Four CPPs were developed and two 
of them (PEP2 and PEP3) were able to disrupt ADAM10/AP2 complex. Preliminary data 
have demonstrated that the most efficient CPP (PEP3) is capable to specifically interfere with 
ADAM10/AP2 association and to increase ADAM10 synaptic localization in vitro. PEP3 was 
selected to perform further in vivo tests. 
 
 
 
(Figure 13) Representative image of the CPP and the therapeutic strategy used. We aim at blocking ADAM10 endocytosis 
by using a peptide that comprises ADAM10/AP2 sequence interaction. This peptide interacts with AP2 and therefore avoid 
its binding on the cytoplasmic tail of the secretase and its internalization. 
 
The specific aim of the thesis was to verify cell peptide candidate efficacy in a mouse model 
of AD (APP/PS1 mice) at different time points and diseases stages, assessing specific 
molecular, structural and behavioral outcomes. 
 
Furthermore, we aimed at improving the CPPs pharmacokinetics profile by developing and 
testing the peptidomimetics in collaboration with Pr. Belvisi (University of Milano) and Dr. 
Di Marino (University of Lugano). 
 
 
 
  
MATERIALS & METHODS 
 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS & METHODS
MATERIALS & METHODS 
 42 
 
1. ANIMALS  
Animals that have been used in the frame of this project for in-vivo testing of the peptide 
were male/female C57/BL6 mice and AD model APP/PS1 mice of 6- 9- and 12-month-old. 
For in-vitro experiments, rat embryos at embryonic day 18 (E18) from Sprague-Dawley rats, 
have been used for the purpose of primary hippocampal neuron cultures. The handling of all 
these animals and the potential surgical procedures were performed with great care taken 
with the ultimate goal to attenuate as much as possible pain and discomfort. The Institutional 
Animal Care and Use Committee of University of Milan and the Italian Ministry of Health 
approved all the experiments involving primary neuronal cultures 
preparation (#326/2015) and mice treatments (#497/2015). All experiments using animal 
models were performed following the ethical guidelines and regulations of the European 
Parliament and of the Council on protection of animals used for scientific purposes (Directive 
of 22 September 2010, 2010/63/EU).  
 
2. PRIMARY HIPPOCAMPAL NEURONS  
In-vitro experiments carried out in the frame of this project were performed on neuronal 
culture. The primary hippocampal neuron cultures were prepared using rat hippocampi at 
embryonic day 18 (E18) and following protocol (Piccoli et al., 2007) as previously described 
in the literature. The cultured neurons at DIV15 were then either treated with active or 
inactive CPP (PEP3) and lysed for further biochemical experiments or transfected for 
imaging.  
 
3. TREATMENTS WITH CELL-PERMEABLE 
PEPTIDES  
The CPP were developed by coupling the active peptides sequence with HIV-1 TAT (Trans-
activating transcriptional activator) derived peptide. The developed peptide is secured under 
patent No.102017000149130. This short basic peptide derived from HIV-1 virus is able to 
deliver successfully a large variety of cargoes such as peptides, proteins and nucleic acids by 
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overcoming the lipophilic barrier of the cellular membranes. The active domain of the CPP is 
comprised in a short (11 amino acids) organization of basic amino acids with the sequence 
YGRKKRRQRRR (Ruben et al 1989). After studies on the interaction domain between the 
sheddase ADAM10 and heterotetrametric complex AP2 we have developed and used an 
active peptide containing the sequence RQR and the inactive alternative peptide EQE 
containing a modified sequence in which arginine residues have been replaced by glutamic 
acids. Adult male and female wild-type mice and transgenic mice have been treated with 
active CPP or its inactive alternative using concentration of 3nmol/g in sterile saline. Peptides 
were administered for 14 days with a daily intraperitoneal injection respecting a precise 
interval of 24 hours between each daily injection. Following the treatment of the animals, 
brains were dissected and rapidly frozen using dry ice prior to be stored at -80°C or pre-fixed 
in paraformaldehyde prior to be used for further experiments.  
 
4. TREATMENTS OF PRIMARY HIPPOCAMPAL 
NEURONS  
For in-vitro treatments, primary hippocampal neuron plated in 60mm petri dish (750,000 
cells/Petri dish) were incubated at DIV14 at 37°C, 5% CO2 with the respective CPP at a 
concentration of 1μM in 2 mL of Neurobasal medium supplemented with B27 for a duration 
of 30 minutes prior to be lysed and/or purified to triton postsynaptic fraction for further 
experiments. 
 
5. HOMOGENIZATION AND PURIFICATION OF 
POSTSYNAPTIC FRACTIONS 
 
The Triton Insoluble Fraction (TIF) is a subcellular fraction dense in synaptic proteins 
present in the PSD (Receptor subunits, signaling molecule, scaffolding proteins, and 
cytoskeletal elements) and absent of any presynaptic markers. Subcellular purification was 
performed and TIF was isolated from mouse half brains and hippocampi after CPP treatment. 
The animals were sacrificed and half brains together with hippocampi were rapidly dissected. 
In order to purify the TIF fractions from half brain, homogenization of the samples was 
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performed at 4°C using 2,5 mL of ice-cold buffer containing protease inhibitors 
(CompleteTM, GE Healthcare, Mannheim, Germany), phosphatase inhibitors (PhosSTOPTM, 
Roche Diagnostics GmbH, Mannheim, Germany), 0.32 M Sucrose, 1 mM Hepes, 1 mM NaF, 
0.1 mM PMSF, 1 mM MgCl2, 1mM NaHCO3 using a hand-held glass-teflon tissue 
homogenizer. An aliquot of homogenate was kept for further analysis of protein levels via 
Western Blotting. In order to further purify the fraction, the centrifugation of the 
homogenates was performed at 1,000g for a duration of 5 minutes at 4°C in order to remove 
white matter and potential nuclear contamination. The supernatant (S1) obtained was further 
centrifuged at 13,000g for a duration of 15 minutes at 4°C. The obtained pellet (P2 crude 
membrane) was then resuspended using hypotonic buffer (1 mM Hepes containing protease 
inhibitors (CompleteTM, GE Healthcare)) and then further centrifuged at 100,000g for 1 hour 
at 4°C. Resuspension of the obtained pellet was performed using glass-glass tissue 
homogenizer prior to let rest the solution at 4°C for 15 minutes in the extraction buffer (1% 
Triton-X-100, 75 mM KCl and protease inhibitors (CompleteTM, GE Healthcare)). After 
extraction, further centrifugation of the samples was performed at 100,000g for 1 hour at 4°C. 
The resulting TIFs were resuspended in 20 mM HEPES buffer containing protease inhibitors 
(CompleteTM, GE Healthcare) using glass-glass homogenizer. 
 
In order to purify the TIF fractions from hippocampi a shorter protocol has been used as 
volumes processed were smaller. Homogenization of the samples were performed at 4°C 
using 800 uL of ice-cold buffer containing protease inhibitors (CompleteTM, GE Healthcare, 
Mannheim, Germany), phosphatase inhibitors (PhosSTOPTM, Roche Diagnostics GmbH, 
Mannheim, Germany), 0.32 M Sucrose, 1 mM Hepes, 1 mM NaF, 0.1 mM PMSF, 1 mM 
MgCl2, 1mM NaHCO3 using a hand-held glass-glass tissue homogenizer. An aliquot of 
homogenate was kept for further analysis of protein levels via Western Blotting. In order to 
further purify the fraction, the centrifugation of the homogenates was performed at 13,000 g 
for a duration of 15 minutes at 4°C. Resuspension of the obtained pellet was performed using 
glass-glass tissue homogenizer prior to let rest the solution at 4°C for 15 minutes in the 
extraction buffer (1% Triton-X-100, 75 mM KCl and protease inhibitors (CompleteTM, GE 
Healthcare)). After extraction, further centrifugation of the samples was performed at 
100,000g for 1 hour at 4°C. The resulting TIFs were resuspended in 20 mM HEPES buffer 
containing protease inhibitors (CompleteTM, GE Healthcare) using glass-glass homogenizer. 
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In order to purify the TIF fractions from primary hippocampal neurons, cells were scraped in 
ice-cold lysis buffer prepared with 0.32 M sucrose, 1 mM Hepes, 1 mM MgCl2, 1 mM 
NaHCO3, 1 mM NaF, 0.1 mM PMSF pH 7.4 and homogenized using glass-glass 
homogenizer. Homogenates from cells were then centrifuged at 1,000g for 15 minutes at 4°C. 
The obtained pellet was then resuspended in 1 mM Hepes buffer containing CompleteTM 
using glass-glass homogenizer. In order to purify the TIF, further centrifugation was 
performed at 13,000g for 15 minutes at 4°C. The pellet obtained was resuspended in 150mM 
KCl, 0.5% Triton and centrifuged at 100,000g for 1 hour at 4°C. The TIF obtained was then 
resuspended in 20mM Hepes buffer containing protease inhibitors (CompleteTM, GE 
Healthcare) using a glass-glass homogenizer. Finally, all protein samples obtained from these 
protocols of purification have been assessed using Bio-Rad protein assay (Hercules, CA, 
USA).  
 
6. PURIFICATION OF SOLUBLE FRACTION  
 
In order to quantify the production of soluble APPα fragment generated by ADAM10 
activity, the Cortex of the mice was homogenized, in an ice-cold lysis buffer prepared with 
EDTA (2mM), EGTA (1mM), PMSF (0,1mM), Hepes (25mM), protease inhibitors 
CompleteTM (1X) and phosphatase inhibitors PhosSTOPTM (1X), using a teflon-glass tissue 
homogenizer at 4°C. The homogenates obtained were then centrifuged for a duration of 10 
minutes at 10,000g in 4°C cold room. The resulting supernatant (S1) was then further 
centrifuged at 4°C for a duration of 1 hour at 100,000g in order to obtain the soluble fraction 
(S2). The resulting soluble fraction (S2) obtained was then used for further ELISA 
experiments.   
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7. ELISA ASSAYS 
 
 
To assess soluble Ab and soluble APPa levels in treated animals we have used different 
ELISA assays for human or mouse/rat metabolites. At early stage of the disease, assessment 
of humanized sAPPa and sAb was performed from cortex together with an assessment of 
mouse/rat sAPPa from hippocampus. At late stage of the disease, assessment of only 
humanized sAPPa and sAb from cortex was performed. This experiment was performed 
using respectively soluble fraction (2S) of the cortex of the animals or Homogenates of the 
hippocampus. 100 µL of prepared standard and test samples were added to the wells. Plate 
was Covered and incubated at 4°c overnight. The next day, liquid was discarded and wells 
were wash 4 times. 100 µL of diluted detection antibody were added to the wells and 
incubated at room temperature for 1 hour. liquid was discarded and wells were wash 5 times. 
100 µL of diluted HRP conjugate were added to each well and incubated at room temperature 
for 30 minutes. After a last set of 5 washes, 100 µL of chromogenic substrate were added to 
each well. Plate was then developed at room temperature in the dark for 30 minutes. After 
this time, 100 µL of stop solution was added to each well. The plate was then evaluated 
within 30 minutes of stopping the reaction. The absorbance of each well was read at 450 nm 
and. A curve-fitting statistical software was used to plot a four-parameter logistic curve fit to 
the standards and then calculate concentrations for the test samples. The concentration of the 
protein of interest was normalized on the total protein concentration and adjusted according 
to the dilution factor used during preparation of the test samples. 
 
 
8. ELECTROPHYSIOLOGY ASSAY 
 
 
Electrophysiological screening of a potential effect of the peptide was performed in 
JANSSEN Pharmaceuticals in Belgium during a secondment. Recordings were performed 
using four setups run simultaneously of 64-channels Micro electrode array system (12µm ø; 
200 µm gap) (Multi Channel System company, Reutlingen, Germany). Acute Sagittal 
hippocampal slices from treated 6-month-old APP/PS1 mice (54 mice), with CA3 region cut 
out to avoid epileptic loops, were placed on the electrodes of the microchips. A stimulation of 
75% of I/O maximum response was set. Stimulation was applied in CA2 Schaffer collaterals 
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and field-Excitatory Postsynaptic Potential were recorded from CA1 pyramidal neurons. 
Using different blockers, the components of the responses were isolated and recorded. The 
AMPA components were recorded during diffusion of nACSF containing bath. The NMDA 
components were recorded during diffusion of nACSF 0,5µM Mg2+, NBQX 10µM (Sigma-
aldrich company, USA) and PTX 10µM (Sigma-aldrich company, USA) containing bath. The 
GluN2A containing NMDA components of the responses were recorded during diffusion of 
nACSF + 0,5µM Mg2+ (Sigma-aldrich company, USA), NBQX 10µM (Sigma-aldrich 
company), PTX 10µM (Sigma-aldrich company, USA), and Ro25 10µM (Hello Bio 
company, UK) containing bath. Signals were then all blocked using APV 50µM (Sigma-
aldrich company, USA) to make sure responses obtained were not composed of artefacts. 
Analysis were performed considering peak response or area of the response. Effect of Input 
Output protocols with incrementation of 5µA from 5 to 100 µA were also recorded. 
Recording software MC Rack was used (Multi Channel System Company, Reutlingen). 
Analysis were performed using Igor Pro 6.37 software (Wavemetrics company). 
 
 
9. DENDRITIC SPINES LABELING 
 
Carbocyanine dye DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate 
('dii'; diic18(3))) (Invitrogen) is a lipophilic membrane stain that diffuses laterally to stain 
neurons. It is weakly fluorescent until incorporated into membranes. The powder form mixed 
into an inert, water-resistant gel was used to stain the spines of the treated mice. The 
following protocol used for spines labeling was previously published (Vicini & Bregman 
2007). First, the intra-cardiac perfusion of the animals through the right atrium was 
performed with PBS 0.1M (room temperature) for about 10 minutes and then with cold 1.5% 
PFA in PB 0.1M. The brain was post-fixed during 40 min in 1.5% PFA in PB 0.1M at 4°C 
and then washed twice with PB 0.1M. The brain was cut coronally around the hippocampal 
region making slices of around 2-3mm in order to have the beginning and end of the 
hippocampus visible. Application of the DiL crystals was performed by touching delicately 
the region of interest on both sides of the coronal slice with needle. The Dil was left in PB 
0.1M covered from the light and at room temperature to diffuse for at least 12 hours. The 
Slice was then fixed in 4%PFA in PB 0.1 M for 45 minutes at 4°C. Coronal slices of 100-150 
um were prepared in PB 0.1M on ice using a vibratome. Slices were finally mount on glass  
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slides with FluoromountTM mounting medium (sigma-aldrich) and seal with nail polish. 
Fluorescence images from slides were then obtained using a Confocal microscope Zeiss 
LSM510 Meta system with an objective 63X performing sequential acquisition at a resolution 
of 1024x1024 pixels.  
 
 
10. CO-IMMUNOPRECIPITATION ASSAYS  
 
 
To immunoprecipitate ADAM10/AP2 protein complex of interest, samples were first 
prepared in a RIA buffer containing 50mM Tris HCl (pH 7.2), 150mM NaCl, 1% NP-40, 
0.5% deoxycholic acid, 0.1% sodium dodecyl sulphate for a volume final of 150μl. Added to 
the samples, 1μl of ADAM10 antibody to precipitate ADAM10 complex. Samples were then 
incubated overnight at 4°C. A control sample was also prepared by incubating in absence of 
the ADAM10 antibody for protein of interest. After the first phase of incubation, a well-
mixed volume of 20µl of A/G beads (Santa-Cruz, Protein A/G Sepharose beads) were added 
to the samples. The samples were then further incubated at room temperature for 2 hours on a 
rotating wheel. Three sets of centrifugations at 12,000g for 5 minutes, together with washes 
with 200ul of RIPA buffer were performed in order to clear beads from unbonded proteins. 
Finally, stop-mix (Containing β-mercaptoethanol) for SDS-PAGE was added to the samples 
and boiled for 10 minutes at 100°C. Prior to load samples, beads were pull-down by short 
centrifugation, and the supernatant was then loaded into 7% SDS-PAGE gels and developed 
via western blot. 
 
 
11. WESTERN BLOTTING 
  
 
Protein samples from homogenates or TIF fractions were prepared and loaded into 7% SDS-
PAGE gels to be separated by electrophoresis at 20mA. Following the electrophoresis, the 
proteins spread on acrylamide gels have been transferred to a 0.45 mm nitrocellulose 
membrane by running them at 240mA for 2 hours in a buffer containing 20% Methanol and 
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1X Blotting buffer (Tris 0,025 M, glicina 0,192 M, MeOH 20%, pH 8.3). After transfer, the 
nitrocellulose membranes have been incubated in iBlock-TBS (Invitrogen, T2015) for at least 
30 minutes. After blocking phase, membranes were subsequently incubated overnight at 4°C 
in primary antibody prepared in iBlock-TBS. After overnight incubation the membranes were 
washed at room temperature three times for a duration of 10 minutes in Tris-Buffered 
Saline/Tween20 (TBS-T). After washes, membranes have been incubated for 1 hour at room 
temperature in horseradish peroxidase-coupled (HRP) secondary antibody (BioRad 
Laboratories) prior to be washed again three times in TBS-T for 10 minutes at room 
temperature. For bands detection, ClarityTM ECL Solution (BioRad Laboratories) was applied 
for 5 minutes on membranes prior to exposition with chemiluminescence trans-UV (302nm) 
using ChemidocTM gel imaging System (Bio-Rad Laboratories). 
 
 
12. CONFOCAL STUDIES  
 
To acquire images of co-localization to test membrane crossing, hippocampal neurons were 
first transfected to express DsRed and imaged live at room temperature. neurons were plated 
on Polylysine-coated Matek dishes at 75,000 cells/well. Transfection was realized between 7 
and 10 DIV and was performed using Ca2+-phosphate DNA transfection protocol. Previously 
present Gibco™ Neurobasal™ medium in Matek dishes was replaced with Gibco™ Mem, 
Glutamax™ (thermos fisher scientific). DNA precipitate was prepared by adding DNA (for 
2µg/well) drop by drop in HeBS (Hepes Buffer Saline solution) pH 7.05 containing: 274 mM 
NaCl, 10 mM KCl, 1.4 mM Na2HPO4, 15mM D-Glucose and 42 mM Hepes; while being 
constantly vortex and let rest in the dark 30 minutes at room temperature. Solution was then 
transfer to the Matek dishes and let to rest 15 minutes at 37°C.  
Microscope was then used to assess presence of residual precipitate. At least 2 washes were 
performed and repeated until complete removal of the precipitate. Matek dishes were placed 
in live imaging chamber and CO2 (5%) together with temperature (37.5°C) was constantly 
computer-monitored. The PEP3 expressing fluorescein was added to Matek dishes at a 
concentration of 1µM and Fluorescence images from cells were then obtained using a 
Confocal microscope Zeiss LSM510 Meta system with an objective 63X performing 
sequential acquisition at a resolution of 1024x1024 pixels. Each image contained up to four 
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0.5μm sections and Z stack projection was performed (Malinverno et al., 2010). The SP5 
CLSM system (Leica-microsystems, Germany) equipped with diode (405nm), argon (488nm) 
and diode pumped solid state (561nm) lasers was used for live imaging of PEP3 membrane 
crossing test. Images were acquired using l20x/1.00w objective (Leica, Germany). 
 
 
 
13.  ANTIBODIES  
 
 
Primary and secondary antibodies used for western-blot, Co-immunoprecipitation or confocal 
studies in the frame of the project are the following: Polyclonal antibody (pAb) anti-
ADAM10 (rabbit) and mAb anti-GluA1 p845 (rabbit) were purchased from Abcam 
Company; anti-ADAM10 (rat) was purchased from R&D; mAb anti-α-adaptin, mAb anti-β2-
adaptin, mAb anti-μ2 and mAb anti-N-Cadherin CTF (C-Terminal Fragment) were purchased 
from BD Science Company; mAb anti-Notch1 was purchased from Cell Signaling Company; 
mAb anti-tubulin and pAb anti-GluN2A were purchased from Sigma Company; mAb anti-
GluR1, mAb anti-GluN2B, mAb anti-GluN1, mAb anti-GluA1 total and mAb anti-PSD-95 
were purchased from Neuromab Company. Peroxidase-conjugated secondary anti-mouse Ab 
were purchased from the Pierce Company. The Peroxidase-conjugated secondary anti-rat Ab 
were purchased from the Abcam Company. Peroxidase-conjugated secondary anti-rabbit Ab 
were purchased from the BioRad company. 
 
14. Y-MAZE TEST  
 
The Y-maze test assesses the ability of the rodents to discriminate a novel environment. This 
test involving the hippocampus does not contain any reinforcements as its methodology 
evaluates the natural propensity of mice to prefer and thereby explore more novelty. The task 
procedure of the test consists of two phases: Sample trial, and test trial. During the sample 
trial, the mouse is placed in the Y-shaped apparatus with 2 arms open for a duration of 5 
minutes. After a retention delay of 30 minutes, the animal is returned for a duration of 5 
minutes in the same Y-maze for the test trial, phase during which a third arm has been open. 
The process of exploration of the mice is captured live during the test using a computer-
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assisted recording system. Only the exploration time of the Novel and familiar arms were 
considered as the statistical analysis was realised calculating the Index of preference for 
either the Familiar arm (time familiar/(time familiar + time novel)) or Novel arm (time 
novel/(time familiar + time novel)). Prior to include mice in the analysis, well performance in 
terms of total exploration time and freezing time were checked to be in accordance with 
preset threshold.  
 
15. NOVEL OBJECT RECOGNITION TEST  
 
The novel object recognition test (NORT) assesses the ability of the rodents to discriminate a 
novel object. As in the Y-maze test, the NORT involves the hippocampus and does not 
contain positive or negative reinforcers. This test evaluates the natural propensity of the mice 
to prefer and thereby explore more a Novel object compared to a Familiar object. Prior to 
performing the test, mice were handled for few minutes for at least 3 days for habituation of 
the mice to the experimenter. The protocol of the test consists of two phases: A first phase of 
familiarization and the actual test phase. During the familiarization phase, the animal was 
exposed to two identical sample objects for 10 minutes directly in its cage. After a retention 
delay of 24 hours, the mice were exposed for a duration of 10 minutes to one of the Familiar 
objects and introduced to a Novel object. During the different phases of the test, the objects 
were placed in the opposite sides of the cage, alternating the position of the respective 
objects. The process of exploration of the mice is captured live during the test using a 
computer-assisted recording system. Only exploration Time of Novel and familiar objects 
were taken in consideration as the analysis was performed by calculating the Index of 
preference for either the Familiar object (time familiar/(time familiar + time novel)) or Novel 
object (time novel/(time familiar + time novel)). Prior to include mice in the analysis, well 
performance in terms of total exploration time and freezing time were checked to be in 
accordance with preset threshold. 
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16. STATISTICAL ANALYSIS AND 
QUANTIFICATION  
 
The quantification of western blotting analysis was performed using a Chemi-fluorescence 
image software (ImageLab, Biorad Company). The different protein levels were quantified as 
optical density (OD) read-outs and were further normalized on tubulin protein OD. However, 
the OD of the C-terminal fragment of N-cadherin and the Phosphorylated p845 Glua1 subunit 
were respectively normalized to the full-length levels and on non-phosphorylated form levels. 
In order to quantify the co-immunoprecipitation of ADAM10/AP2 complex, the different 
subunits of AP2 were normalized on the OD of ADAM10 total levels. The different values 
have been expressed as mean ± Standard Error of the Mean (SEM). Annotated N numbers 
represent the number of animals used for the in vivo experiments while when testing in vitro 
N numbers represent the replicates of the experiments. Spines morphology analysis was 
performed using Image-j software. Statistical tests for the significance of the data were 
performed as appropriate, by Student t-test or by One-way or Two-way ANOVA followed by 
Bonferroni Post-hoc test (Two-way ANOVA using data from four experimental groups: Tg 
PEP3, Tg inPEP3, WT PEP3, WT inPEP3). Finally, graphic representations have been 
realized using Prism software. 
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1. Testing PEP3 treatment at full-blown stage of 
Alzheimer’s disease in APP/PS1 mice. 
 
1.1. Alzheimer’s disease mouse model: APP/PS1 mice 
Previous in-vitro experiments performed testing 4 different CPPs in our laboratory, leaded to 
the conclusive observation concerning PEP3 as representing a promising agent for further in-
vivo testing (data not shown). As first, the efficacy in-vivo of the selected active peptide 
(PEP3) was assessed in wild-type mice. The agent PEP3 was observed to cross the blood-
brain barrier (BBB) as, after an acute intraperitoneal injection, the peptide was detected via 
immunohistochemistry in the brain parenchyma of the animals (data not shown). Toxicology 
study revealed that PEP3 did not have any toxic effect on the wild-type mice and did not lead 
to any systemic or organ-specific failure or damages (data not shown).  
Following these tests, the present study focuses on the test of PEP3 in a mouse model of AD. 
The APP/PS1 mouse model of AD was used as to test PEP3 at different stages of the 
pathology in these animals. These transgenic mice have been generated by co-injecting two 
vectors encoding for a mutant APP and mutant PS1.138 The APP sequence encodes for a 
chimeric mouse/human form of APP (Mo/HuAPP695swe) carrying the Swedish mutation 
under the mouse prion protein promoter which leads to overexpression of humanized APP 
protein in the CNS of these mice. The PS1 sequence encodes human presenilin-1 lacking 
exon 9 (dE9) under the mouse prion protein promoter leading to increased cleavage of APP 
and overproduction of Ab1-42 peptide. Therefore, these mice represent a good model of 
amyloid-related pathology as they develop plaques and show synaptic loss around the age of 
6-month-old, which is to be considered as an early stage of the disease. At full-blown 
pathology, considered to initiate around 9- to 12-month-old these mice start to present strong 
neuronal loss associated with severe cognitive deficits. These cognitive deficits have been 
observed at 12-month-old by use of Morris water maze behavioural tests, however cognitive 
impairments are assumed to be present before this age as due to synaptic loss. (Figure-1).
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(Figure 1) Scheme describing time-related phenotype of APP/PS1 mice used to test PEP3 in-vivo. These mice develop 
Amyloid Plaques and Gliosis associated with changes in synaptic transmission and synaptic loss by 6 months of age 
which represents the early stage of the disease. At full-blown pathology, considered to start around 9 to 12-months-old, 
the mice show important neuronal loss associated with severe cognitive impairment. (Scheme credit: Modified from 
Alzheimer forum: https://www.alzforum.org/research-models/appswepsen1de9-0) 
 
1.2. Treatment with PEP3 efficiently increases ADAM10 
synaptic localization 
 
In order to study the efficacy of the peptide to interfere with the interaction between 
ADAM10 and AP2 subunit b2-adaptin in this mouse model of AD, we performed a 14-days 
treatment of 9-month-old APP/PS1 mice, consisting of a daily intraperitoneal injection of 
PEP3 at 3nmol/g (Figure-2 A). An inactive peptide appropriately designed was used at the 
same dose as negative control in all experiments (inPEP3).  
 
The forebrain of the animals was lysated and the homogenate was used to assess 
ADAM10/AP2 interaction. Co-immunoprecipitation assay was performed in order to 
quantify the effect of the peptide on the interaction between these two respective proteins. 
We precipitated the protein complex using anti-ADAM10 antibody and observed an 
increased association of around 60% between ADAM10 and the b2-adaptin subunit of AP2 
in the transgenic mice treated with control peptide inPEP3 compared to wild-type animals. 
Interestingly, the treatment with PEP3 reduces the ADAM10/AP2 interaction in APP/PS1 
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mice to a level comparable to one of wild-type mice (Figure-2 B and C). The statistical 
analysis showed that the treatment of the transgenic mice with PEP3 leaded to significantly 
lower ADAM10/AP2 association levels (β2-adaptin Tg PEP3: 72.53% ±16.46%, N=9) 
compared to transgenic mice treated with inPEP3 (β2-adaptin Tg inPEP3: 159.9% ±47.78%, 
N=9), which presented increased ADAM10/AP2 association levels and in same manner 
comparable to the increased association observable in AD patients.118  
(Figure 2) Assessment of PEP3 effect on 9-month-old APP/PS1 and wild-type mice. (A) Experimental paradigm scheme of 
the 14-days treatment with a daily intraperitoneal injection with either PEP3 or inPEP3 at a concentration of 3nmol/g. (B) 
Brain homogenates were immunoprecipitated using anti-ADAM10 antibody and β2-adaptin co-precipitation was evaluated 
considering Optical Density (OD). (C) OD quantification of co-immunoprecipitation experiment in B. Significantly higher 
ADAM10/AP2 interaction was observed in the transgenic mice treated with inPEP3 (β2-adaptin Tg inPEP3: 159.9 ±47.78, 
N=9; Two-way ANOVA: ***p=0.0006) compared to transgenic mice treated with PEP3 (β2-adaptin Tg PEP3: 72.53 ±16.46, 
N=9), which presented ADAM10/AP2 interaction levels comparable to wild-type animals. (D) Representative immunoblot 
of ADAM10 Western blotting (WB) analysis of homogenate and TIF fraction. (E) OD quantification of WB experiment in D. 
No significant differences were observed in the homogenate. In the TIF fraction, OD ratio between ADAM10 and tubulin 
revealed a significantly increased ADAM10 synaptic availability in APP/PS1 mice treated with PEP3 (ADAM10 Tg PEP3: 
84.19 ±14.07, N=9) compared to the transgenic animals treated with inPEP3 (ADAM10 Tg inPEP3: 54.58 ±7.90, N=9; 
Two-way ANOVA: **p=0.0081). 
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Thus, confirming that the unbalance of ADAM10 endocytosis is also present in this mouse 
model of AD. This unbalance in ADAM10 local trafficking can be considered as a “synaptic 
trait” of the pathology. Indeed, the impairment of ADAM10 synaptic availability could lead 
to a decrease of a-secretase activity on APP with a concomitant increase of b-secretase 
activity. In light of these consideration, the rescue of this impairment of the synaptic 
trafficking of ADAM10 could enhance ADAM10 activity towards APP; therefore, 
representing a promising therapeutic approach for the development of a disease modifying 
agent. 
 
To assess whether the disruption of the ADAM10/AP2 protein complex by PEP3 treatment 
could affect the synaptic localization of ADAM10, we measured ADAM10 synaptic levels in 
triton-insoluble fraction (TIF), that is enriched in postsynaptic proteins, purified from the 
forebrains collected from the same pool of previously treated APP/PS1 mice. Western blot 
analysis of ADAM10 in total homogenate and TIF, revealed a decrease by around 50% of 
ADAM10 synaptic levels in the transgenic mice treated with inPEP3 compared to the wild-
type animals. These data confirm that the aberrant increase in ADAM10/AP2 association is 
accompanied to a decrease in ADAM10 synaptic availability. Interestingly, in the APP/PS1 
mice treated with PEP3 (ADAM10 Tg PEP3: 84.19% ±14.07%, N=9), we observed a 
significant increase of ADAM10 synaptic levels when compared to inPEP3-treated APP/PS1 
mice (ADAM10 Tg inPEP3: 54.58% ±7.90%, N=9). No significant differences were 
observed in the homogenate when comparing the experimental groups, suggesting that the 
expression of the protein is not affected. In the APP/PS1 mice treated with PEP3, ADAM10 
synaptic levels have been observed comparable to ADAM10 synaptic levels in wild-type 
mice (Figure-2 D and E). Thus, showing that active PEP3 was able to rescue the drop of 
ADAM10 synaptic levels and reverse it to the wild-type level. The effect of the active peptide 
on ADAM10/AP2 complex is positively affecting ADAM10 synaptic levels and could 
increase the a-secretase activity of the sheddase on APP; therefore, counteracting the activity 
of the b-secretase BACE1. This increase in the a-secretase activity is a key mechanism by 
which the peptide could have strong disease modifying features.  
 
 
RESULTS 
 58 
1.3. Treatment with PEP3 decreases Ab levels without 
changing sAPPa release in APP/PS1 mice 
 
After observing the disruption of ADAM10/AP2 interaction and the enhancement of 
ADAM10 synaptic localization, we decided to further investigate the repercussion of the 
treatment on the APP protein processing via assessment of resulting metabolites. The 
assessment of metabolites of the APP protein processing is essential to screen ADAM10 a-
secretase activity. The purification of soluble fraction from the cortex of the animals was 
performed. We used ELISA kits to measure human sAPPa and Aβ1-42 levels in order to 
analyse PEP3 effect. The treatment with PEP3 in the transgenic mice did not affect the 
human soluble APPa release since the levels of this metabolite were comparable with 
transgenic mice treated with inPEP3 (Figure-3 A). These results suggest that an increase in 
ADAM10 synaptic availability cannot counteract the effect of the Swedish mutation of APP 
transgene that promotes β-cleavage of APP. The levels of Aβ1-42 in the cortex of APP/PS1 
mice treated with PEP3 were significantly lower (Tg sAb PEP3: 4.471 ±0.4509, N=9) 
compared to the transgenic mice treated with inPEP3 (Tg sAb inPEP3: 6.149 ±0.6307, N=8) 
(Figure-3 B). We can hypothesize that the decrease in human Aβ1-42 could be ascribed to an 
increased degradation of the peptide rather than to a shift of APP metabolism towards the 
non-amyloidogenic pathway.  
 
(Figure 3) ELISA assays were performed to assess metabolites levels in the cortex of the treated 9-month-old 
APP/PS1 mice with either inPEP3 or PEP3. (A) ELISA assays were performed to assess human sAPPa levels in 
the cortex of the transgenic mice. No significant difference was observed in the APP/PS1 mice (Tg sAPPa inPEP3: 
3.796 ± 0.2520, N=9; Tg sAPPa PEP3: 3.843 ±0.3455, N=9). (B) ELISA assays were performed to assess sAb 
levels in the cortex of transgenic mice treated either with PEP3 or inPEP3. A significant decrease in sAb levels was 
observed in the transgenic mice treated with PEP3 (Tg sAb PEP3: 4.471 ±0.4509, N=9) compared to mice treated 
with inPEP3 (Tg sAb inPEP3: 6.149 ±0.6307, N=8; t-test: *p<0.0438). 
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1.4. Treatment with PEP3 affects synaptic levels of NMDAR 
subunits 
 
To understand the impact of the cell-permeable peptide on different potential mechanisms 
implicated in the synaptic transmission, different synaptic proteins were screened. The levels 
of the main subunits of NMDAR and AMPAR, that are crucial for synaptic transmission and 
plasticity mechanisms, were screened in TIF and homogenate of the same pool of treated 9-
month-old APP/PS1 mice. No significant differences among the experimental groups were 
observed in the homogenate of the forebrain of the treated mice, suggesting that the treatment 
does not affect the expression of relevant synaptic proteins.  
 
In the TIF, no significant differences were observed in levels of GluA1 subunit of the 
AMPAR. In addition, we measured the phosphorylation levels at the Ser845 that is relevant 
for the AMPAR regulation, but no significant differences were detected.139 No differences 
were observed in synaptic levels of the GluN2B subunit of the NMDAR. Interestingly, a 
decrease of GluN2A subunit synaptic levels of around 30% was observed in the transgenic 
mice treated with the inPEP3 compared to wild-type animals.  
 
Statistical analysis showed that the transgenic mice treated with PEP3 present a significant 
increase of GluN2A synaptic levels (GluN2A Tg PEP3: 96.54 ±5, N=9) compared to 
transgenic mice treated with inPEP3 (GluN2A Tg inPEP3: 67.93 ±6, N=9) (Figure-4 A and 
B). Thus, showing that active PEP3 was able to rescue the drop of GluN2A subunit synaptic 
levels and reverse it to the wild-type level. This effect of PEP3 on the synaptic levels of a 
subunit of NMDAR clearly represent a mechanism by which synaptic transmission could be 
improved in the transgenic animals.  
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(Figure 4) Synaptic proteins assessment after 14-days treatment of 9-month-old APP/PS1 and wild-type mice with 
either inPEP3 or PEP3. (A) Representative immunoblot of synaptic proteins WB analysis using homogenate and TIF 
fraction of treated transgenic mice (B) OD quantification of WB experiments (only TIF) in A. Significantly higher 
GluN2A synaptic levels were observed in the transgenic mice treated with PEP3 (GluN2A Tg PEP3: 96.54 ±5, N=9; 
t-test: **p<0.0040, inPEP3 Tg vs PEP3 Tg) compared to the transgenic mice treated with inPEP3 (GluN2A Tg 
inPEP3: 67.93 ±6, N=9). No significant differences were observed in GluN2B levels, p845 GluA1 phosphorylation 
levels nor in total GluA1 levels. 
 
 
1.5. Treatment with PEP3 does not improve cognition in 
APP/PS1 mice at full-blown pathology 
 
Investigation of the effect of PEP3 treatment on the behaviour was performed in order to 
understand to which extent these changes in NMDAR subunits at the synapse could improve 
the synaptic transmission underlying the cognitive processes, and thereby rescue a potential 
cognitive deficit in these mice. A commonly used NORT (Novel Object Recognition Test) 
was performed at the end of a 14-days treatment, of 12-month-old transgenic and wild-type 
mice, with either the inPEP3 or PEP3. The NORT, based on animals’ preference to explore 
novelty, is involving the hippocampus through spatial recognition and memory processes, 
giving a robust readout on potential cognitive impairment. Mice were exposed to two 
identical objects for 10 minutes and after 24 hours were re-exposed to one identical object 
(FAMILIAR) and one completely different object (NOVEL). Analysis of the videos captured 
during the test, showed that the wild-type mice prefer to explore the novel object (WT 
preference index Novel: 0.5425 ±0.0254, N=10) compare to Familiar object (WT preference 
index Familiar: 0.4575 ±0.0254, N=10). The results of this test have confirmed the 
conserved cognitive function of the wild-type animals even at this advanced age (Figure-5 A 
and D). However, no differences of preference index were observed in transgenic mice 
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(Figure-5 B and C). The transgenic mice either treated with the inPEP3 or PEP3 were 
cognitively impaired. These data showing no effect of the peptide on the rescue of the 
behaviour of these mice at this stage of the pathology. This result might be due to the far too 
advanced stage of the disease in these transgenic mice. Previous studies at full-blown 
pathology have already observed abundant plaques in the hippocampus of these mice together 
with neuronal loss adjacent to these plaques.140 This neuronal loss could irreversibly affect 
cognition of the transgenic mice, thus preventing the synaptic effect of PEP3 to be sufficient 
in order to reverse the cognitive impact of neuronal death. 
 
(Figure 5) Behavioral read-out of the effect of PEP3 was performed via NORT with APP/PS1 and wild-type mice 
treated 14 days with either the PEP3 or inPEP3. (A) Representation of preference index for familiar and novel 
object in wild-type mice treated with inPEP3. A significant preference for the novel object was observed in this 
group after 24 hours (WT preference index FAMILIAR: 0.4575 ±0.02540, N=10; WT preference index NOVEL: 
0.5425 ±0.02540, N=10; t-test: *p=0.0294 Novel vs Familiar). (B) Representation of preference index for familiar 
and novel object in APP/PS1 mice treated with inPEP3. No significant differences of preference index were 
observed in this group after 24 hours (Tg inPEP3 preference index FAMILIAR: 0.5370 ±0.05548, N=10; Tg inPEP3 
preference index NOVEL: 0.4630 ±0.05548, N=10). (C) Representation of preference index for familiar and novel 
object in APP/PS1 mice treated with PEP3. No significant differences of preference index were observed in this 
group after 24 hours (Tg PEP3 preference index FAMILIAR: 0.5346 ±0.04969, N=10; Tg PEP3 preference index 
NOVEL: 0.4654 ±0.04969, N=10). (D) Representation of preference index for novel object for the three different 
experimental conditions. Data analysis shows significant single t-test of Novel object preference index for wild-type 
treated with inPEP3 (Novel object Actual Mean 0.614> chance level 0.50, N=10; single t-test **p=0.0477). 
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1.6. Screening for pathology onset in APP/PS1 mice 
 
These interesting data obtained treating APP/PS1 mice at full-blown pathology with PEP3 
showed us the potential of such therapeutic action targeting ADAM10. Moreover, we also 
observed a similar defect of ADAM10 local trafficking mechanisms, as observed in AD 
patients, such as an increase in ADAM10/AP2 interaction and a decrease of ADAM10 
synaptic levels compared to physiological levels. These biochemical changes are most likely 
to impact mice cognition at full-blown pathology, however at this stage the biochemical 
changes must be combined and diluted with different pathological mechanisms far too 
advanced such as accumulation of amyloid plaques, neuronal loss and a strong inflammatory 
response that could affect the behaviour. In order to assess the efficiency of PEP3 on the 
behaviour via its action on ADAM10 synaptic localization we decided to screen for the onset 
window during which these biochemical changes appear.  
 
We assessed ADAM10 interaction with AP2 and its synaptic levels at different time points to 
be able to treat during the onset of the pathological changes in ADAM10 trafficking. The 
analysis revealed that changes appear before 9-month-old, as already at 6-months-old, since 
an increase of ADAM10/AP2 association is observed together with a decrease of ADAM10 
synaptic levels in APP/PS1 mice. Indeed, co-immunoprecipitation of ADAM10 and the AP2 
subunit b2-adaptin revealed significantly higher levels of association with b2-adaptin in the 
6-month-old APP/PS1 transgenic mice (Tg b2-adaptin 6mo: +134% ±43.1%, N=3) compared 
to the wild-type mice at the same age (Figure-6 A and B). Western blotting revealed 
significantly lower synaptic levels of ADAM10 in the 6-month-old APP/PS1 transgenic mice 
(Tg ADAM10 6mo: -57.5% ±7.9%, N=3) compared to the wild-type mice at the same age 
(Figure-6 C and D). These differences observed at 6-month-old were not observed in 
APP/PS1 mice at the age of 3 months. Therefore, in light of these results we decided to treat 
APP/PS1 mice at the age of 6 months, at the onset of the ADAM10 trafficking alteration.
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(Figure 6) Assessment of target parameters of PEP3 in APP/PS1 mice and wildtype mice at 3- and 6-month of age. 
(A) Brain homogenates were immunoprecipitated using anti-ADAM10 antibody and β2-adaptin co-precipitation was 
evaluated considering Optical Density. (B) A significant increase of the interaction was observed in the 6-month-old 
transgenic mice (Tg β2-adaptin 6mo: 234.0 ±43.1, N=3; t-test: *p=0.0358; Two-way ANOVA: *p=0.0202) compared 
to wildtype mice at the same age. No significant changes in ADAM10 interaction with AP2 were observed at 3-
month-old. (C) Representative immunoblot of ADAM10 WB analysis in TIF fraction. (D) OD quantification of WB 
experiments in TIF of transgenic mice and wildtype mice at 3- and 6-month of age. In the TIF fraction, OD ratio 
between ADAM10 and tubulin revealed a significant decrease in ADAM10 synaptic levels in 6-month-old transgenic 
mice (ADAM10 Tg 6mo: 42.5 ±7.9, N=3; t-test: *p=0.0184) compared to the wild-type mice at the same age. No 
significant change in ADAM10 synaptic levels were observed at 3-months-old. 
 
 
2. Testing PEP3 treatment at early stage of 
Alzheimer’s disease in APP/PS1 mice. 
 
2.1. Treatment with PEP3 efficiently increases ADAM10 
synaptic localization at early stage of the disease 
 
We have performed a 14-days treatment of daily intraperitoneal injections of 3nmol/g of 
either PEP3 or inPEP3 in 6-month-old APP/PS1 and wild-type mice (Figure-7 A). Following 
the treatment, the forebrain of the animals was lysated and the homogenate was used to assess 
ADAM10/AP2 interaction. As previously shown, a co-immunoprecipitation was performed 
in order to confirm the efficacy of the peptide in disrupting the interaction between ADAM10 
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and AP2. We have precipitated the complex using anti-ADAM10 antibody which confirmed 
that the APP/PS1 mice treated with inPEP3 present an increased association between 
ADAM10 and the b2-adaptin subunit of AP2 by around 95% compared to wild-type animals. 
The PEP3 treatment significantly reduces this aberrant increased association and restores the 
levels of interaction to the ones detected in wild-type mice. 
 
 
(Figure 7) Assessment of PEP3 effect on 6-month-old APP/PS1 and wild-type mice. (A) Experimental paradigm 
scheme of the 14 days treatment with daily intraperitoneal injections with either PEP3 or inPEP3 at a concentration 
of 3nM/g of body weight. (B) Brain homogenates were immunoprecipitated using anti-ADAM10 antibody and β-
adaptin co-precipitation was evaluated considering Optical Density. (C) OD quantification of co-immunoprecipitation 
experiment in B. A significant increase of the interaction was observed in the transgenic mice treated with inPEP3 
(β2-adaptin Tg inPEP3: 196.8 ±51.18, +96.8% ±51.1% N=9) while the treatment with PEP3 restored the 
AP2/ADAM10 interaction levels to levels similar to the ones of inPEP3-treated wild-type mice (β2-adaptin Tg PEP3: 
87.22 ±17.94, -17.78% ±17.94%, N=9, One-way ANOVA: *p=0.0314). (D) Representative immunoblot of ADAM10 
WB analysis in Homogenate and TIF fraction. (E) OD quantification of WB experiment in D. No significant 
differences were observed in the homogenate. In the TIF fraction, optical density ratio between ADAM10 and 
tubulin revealed a significant (t-test: *p=0.0382) decrease in ADAM10 synaptic levels in transgenic animals treated 
with the inPEP3 (ADAM10 Tg inPEP3: 69.94 ±3.3, -30.1% ±3.3%, N=7) compared to the animals treated with the 
PEP3 (ADAM10 Tg PEP3: 114.8 ±18.97, +14.8% ±18.9%, N=7) which have levels comparable to wild-type mice. 
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Indeed, the quantitative analysis showed that the transgenic animals treated with PEP3 have 
significantly lower ADAM10/AP2 interaction levels (Tg PEP3: 82.22% ±17.94% N=9) 
compared to the transgenic mice treated with inPEP3 (Tg inPEP3: 196.8% ±51.1% N=9) 
(Figure-7 B and C). To assess the functional efficacy of the peptide in increasing ADAM10 
synaptic levels at early stage of the disease we performed a TIF purification of the forebrain 
from the same pool of 6-month-old mice. 
 
The statistical analysis revealed that APP/PS1 mice treated with inPEP3 presented 
significantly lower ADAM10 synaptic levels by around 30 % (ADAM10 Tg inPEP3: 69.94% 
±3.3%, N=7) compared to wild-type animals treated with inPEP3. The treatment with PEP3 
reverses the ADAM10 synaptic levels to wild-type levels, restoring its synaptic availability 
(ADAM10 Tg PEP3: 114.8% ±18.97%, N=7). No significant differences in ADAM10 total 
levels were observed in the homogenates (Figure-7 D and E). These encouraging data 
confirmed the efficacy of the peptide PEP3 in acting on ADAM10 synaptic levels at early 
stage of the pathology. 
 
 
2.2. Treatment with PEP3 improves cognition in APP/PS1 
mice at early stages of the disease 
 
 
In order to test the effect of PEP3 on the behaviour of the APP/PS1 mice line previously used 
for molecular analysis, a behaviour test was performed to assess cognitive function of these 
mice. Animals treated during this experiment were 6-month-old APP/PS1 mice as considered 
at early stage of the disease. Like previously, a NORT (Novel Object Recognition Test) was 
performed at the end of a 14-days treatment with either inPEP3 or active PEP3. As observed 
at full-blown pathology, the analysis of the videos captured during the test, showed that the 
wild-type mice prefer to explore the novel object (WT preference index NOVEL: 0.6119 
±0.0276, N=9) compared to the familiar object (WT preference index FAMILIAR: 0.3881 
±0.0276, N=9). The results of this test have confirmed the conserved cognitive function of 
wild-type animals (Figure-8 A). No differences of preference index were observed in 
transgenic mice treated with the inPEP3 (Figure-8 B). These mice did not show a clear 
preference for the novel or familiar object, indicating that the mice were unable to 
discriminate between the two objects, a feature underlying a cognitive impairment. 
Interestingly, in mice treated with PEP3 a clear preference was observed for the novel object 
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(Tg PEP3 preference index NOVEL: 0.5953 ±0.0311, N=8) compared to the familiar object 
(Tg PEP3 preference index FAMILIAR: 0.4047 ±0.0311, N=8) (Figure-8 C). By comparing 
the preference index against the chance level, it is clear that PEP3 treatment completely 
reverts the cognitive impairment of the APP/PS1 mice (Figure-8 D). 
 
 
(Figure 8) Novel object recognition test performed on 6-month-old transgenic and wild-type mice treated 14 days 
with either inPEP3 or PEP3. Statistical analysis was performed by calculating the preference index for the Familiar 
object (time exploring familiar/(time exploring familiar + time exploring novel)) and Novel object (time novel/(time 
familiar + time novel)). (A) Data from NORT. Representation of data showing a significantly higher preference index 
of the wild-type mice for the Novel object (WT inPEP3 preference index NOVEL: 0.6119 ±0.0276 N=9) compared to 
the familiar object (WT inPEP3 preference index FAMILIAR: 0.3881 ±0.0276 N=9; t-test **p=0.0037). (B) Data from 
NORT. Representation of data showing no significant difference of preference index between Familiar and Novel 
object in transgenic mice treated with inPEP3. (C) Data from NORT. Representation of data showing a significantly 
higher preference index of the transgenic mice treated with PEP3 for the Novel object (Tg PEP3 preference index 
NOVEL: 0.5953 ±0.0311, N=9) compared to the familiar object (Tg PEP3 preference index FAMILIAR: 0.4047 
±0.0311 N=8; t-test *p=0.0183 Familiar vs Novel). (D) Representation of preference index for novel object for the 
three different experimental conditions. Data analysis shows significant single t-test for Novel object preference 
index for wild-type mice treated with inPEP3 (Novel object Actual Mean: 0.611> chance level: 0.50, N=9; single t-
test **p=0.0037) and transgenic mice treated with PEP3 (Novel object Actual Mean: 0.595> chance level: 0.50, 
N=8; single t-test *p=0.0187). 
 
These results suggest that PEP3 treatment induces an improvement of the cognitive functions. 
In order to confirm these interesting results, and to obtain a second behavioral read-out of the 
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effect of PEP3 on the cognitive function, we performed a Y-maze test. This test is based on 
the free exploration of an apparatus with three arms; in the first 5 minutes of exploration, one 
arm is closed while in the second phase of 5 minutes of exploration all the arms are 
accessible. The Y-maze test involves the hippocampus through spatial recognition and 
memory processes. 
 
 
 
(Figure 9) Y-Maze test performed on 6-month-old transgenic and wild-type mice treated 14 days with either inPEP3 
or PEP3. Statistical analysis was performed by calculating the preference index for the Familiar arm (time exploring 
familiar/(time exploring familiar + time exploring novel)) and Novel arm (time exploring novel/(time exploring familiar 
+ time exploring novel)). (A) Data from Y-maze test. Representation of data showing a significantly higher 
preference index of the wild-type mice for the Novel arm (WT inPEP3 preference index NOVEL: 0.6142 ±0.0301, 
N=10) compared to the familiar arm (WT inPEP3 preference index FAMILIAR: 0.3858 ±0.0301, N=10; t-test 
**p=0.0043 Familiar vs Novel). (B) Data from Y-maze test. Representation of data showing no significant difference 
of preference index between Familiar and Novel arm in transgenic mice treated with inPEP3. (C) Data from Y-maze 
test. Representation of data showing a significantly higher preference index of the transgenic mice treated with 
PEP3 for the Novel arm (Tg PEP3 preference index NOVEL: 0.6065 ±0.191, N=9) compared to the familiar arm (Tg 
PEP3 preference index FAMILIAR: 0.3935 ±0.191, N=9; t-test ***p=0.0005 Familiar vs Novel). (D) Representation 
of preference index for novel object for the three different experimental condition. Data analysis shows significant 
single t-test of Novel arm preference index for wild-type mice treated with inPEP3 (Novel object Actual Mean: 
0.614> chance level 0.50, N=10; single t-test **p=0.0043) and transgenic mice treated with PEP3 (Novel arm 
Actual Mean: 0.606> chance level, 0.50, N=9; single t-test ***p=0.0005). 
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Like previously the behaviour test was performed at the end of a 14-days treatment with 
either 3nmol/g of inPEP3 or PEP3 using intraperitoneal administration route. Following the 
treatment, the test was performed in accordance to standard protocol in use for this test. As 
observed in the NORT, the analysis of the videos captured during the test, showed that the 
wild-type mice treated with inPEP3 prefer to explore the Novel arm (WT inPEP3 preference 
index NOVEL: 0.6142 ±0.0301, N=10) compared to Familiar arm (WT inPEP3 preference 
index FAMILIAR: 0.3858 ±0.0301, N=10). These results confirmed the conserved cognitive 
function of the wild-type animals (Figure-9 A). No differences of preference index were 
observed in transgenic mice treated with inPEP3 (Figure-9 B). These mice did not show a 
preference for the Novel or Familiar arm, indicating that they were unable to discriminate 
between the two objects, which indicate a cognitive impairment. Confirming data obtained 
with NORT, the transgenic mice treated with PEP3 showed a preference for novel arm (Tg 
PEP3 preference index NOVEL: 0.6065 ±0.191, N=9) compared to the Familiar arm (Tg 
PEP3 preference index FAMILIAR: 0.3935 ±0.191, N=9) (Figure-9 C). By comparing the 
preference index against the chance level, it is clear that PEP3 treatment completely reverts 
the cognitive impairment of the APP/PS1 mice as previously observed in the NORT (Figure-
9 D). 
 
2.3. Treatment with PEP3 affects synaptic levels of NMDAR 
subunits 
 
In light of these results, we decided to assess different synaptic proteins to understand the 
impact of PEP3 on major actors implicated in the synaptic transmission. Prior results at full-
blown pathology showed a decrease of GluN2A synaptic levels in the APP/PS1 mice but no 
differences in the homogenates. We decided to focus on the analysis of the TIF fraction from 
the hippocampus as its involvement in learning and memorisation process is crucial. We 
screened major subunits of NMDAR and AMPAR that are underlying synaptic transmission 
and plasticity mechanisms. No significant differences were observed for GluA1 subunit of 
the AMPAR and its level of phosphorylation at Ser845. Interestingly, no difference in 
GluN2A subunit synaptic level were observed in the transgenic mice treated with inPEP3 
(GluN2A Tg inPEP3: 107% ±9%, N=9) compared to wild-type mice. However, the 
transgenic mice treated with PEP3 presented significantly higher GluN2A synaptic levels 
(GluN2A Tg PEP3: 154.6% ±20%, N=9) compared to transgenic mice treated with inPEP3 
(Figure-10 A and B). This observation regarding GluN2A confirmed the effect of PEP3 as 
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enhancer of the synaptic levels of GluN2A subunits like previously shown in mice at full-
blown pathology. At early stages of the disease, GluN2B subunits are also tending to increase 
in the transgenic mice treated with PEP3 (GluN2B Tg PEP3: 163.5% ±35%, N=9), however 
this change is not observed to be significant as compared with inPEP3 condition. NMDAR 
are essential in synaptic plasticity and synapse formation underlying learning and memory 
processes. This effect of PEP3 on the synaptic levels of the subunit of NMDAR clearly 
represents an important mechanism by which PEP3 could improve synaptic transmission in 
transgenic mice. Therefore, investigation of the effect of the peptide on synaptic transmission 
was investigated during a secondment in Janssen Pharmaceuticals. 
 
 
(Figure 10) Synaptic proteins assessment after treatment of 9-month-old APP/PS1 and wild-type mice with either 
inPEP3 or PEP3. (A) Representative immunoblot of synaptic proteins WB analysis from hippocampus TIF of the 
treated transgenic mice. (B) OD quantification of WB experiment in A. Significantly higher GluN2A levels were 
observed in the transgenic mice treated with PEP3 (GluN2A Tg PEP3: 154.6 ±20.26, N=9; t-test: **p<0.0290) 
compared to transgenic mice treated with inPEP3 (GluN2A Tg inPEP3: 100.7 ±9.73, N=9) in which GluN2A levels 
is comparable to wild-type levels. No significant difference was observed in Ser-845 GluA1 phosphorylation levels 
nor in total GluA1 levels. A trend regarding GluN2B was observed as PEP3 tend to increase GluN2B synaptic 
levels (GluN2B Tg PEP3: 163.5 ±35.67, N=9) however, no significant difference was observed as compared to 
inPEP3 condition (GluN2B Tg inPEP3: 98.86 ±16.76, N=7). 
 
 
2.4. Electrophysiological effect of the treatment with PEP3 
 
During my secondment in Janssen Pharmaceuticals in Belgium, we tested the effect of PEP3 
on the neuronal activity in the hippocampus. Using Multi Electrode Array setup, we recorded 
field Excitatory Postsynaptic Potential (fEPSP) of AMPA/NMDA and NMDA-isolated 
components of the response from acute hippocampal slices of treated mice. The experimental 
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plan was composed of four groups: wild-type mice and transgenic APP/PS1 mice treated with 
inPEP3 and PEP3 (APP/PS1 line:”B6.Cg-Tg(Thy1-APPSw,Thy1PSEN1*L166P)21Jckr”).141 
 
 
No significant differences between the experimental groups were observed in the area and 
amplitude of the NMDA components (Figure-11 A and B). A paired-pulse ratio protocol was 
also performed while recording the NMDA component, however no differences and potential 
implication of pre-synaptic mechanisms were observed (Figure-11 C). Finally, the results 
obtained via input/output protocols confirmed the absence of impairment of the synaptic 
transmission in the transgenic animals as the responses to the protocol were similar to the 
wild-type responses (Figure-11 D).  
 
Overall, these results do not show any difference in NMDAR and AMPA currents. However, 
the transgenic line used in Janssen is slightly different from the APP/PS1 line used for the 
biochemical and behavioural experiments in Milan, since these mice overexpress a human 
APP transgene (HuAPP-KM670/671NL), while the APP/P1 mice used in biochemical and 
behavioural experiments based in Milan overexpress a chimeric mouse/human APP 
(Mo/HuAPP695swe).141  
 
The APP/PS1 mice used for the electrophysiological experiments did not display synaptic 
deficit, neither cognitive deficits and nor decrease in ADAM10 synaptic levels revealed by 
further biochemical analysis (Data not shown). Therefore, we decided to focus our research 
on APP/PS1 mice showing impairment of ADAM10 synaptic availability. 
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(Figure 11) Electrophysiological Multi-Electrode Array (MEA) experiment performed on acute hippocampal slices 
from treated transgenic or wild-type mice for 14 days with either inPEP3 or PEP3. (A) Analysis of AMPA-normalized 
area of NMDA f-EPSP component from APP/PS1 and wild-type animals treated with PEP3 or inPEP3. No 
significant difference was observed among the different experimental groups (NMDA Tg PEP3: 1.375 ±0.3953, 
N=27; NMDA WT PEP3: 1.444 ±0.3809, N=29; NMDA Tg inPEP3: 0.9805 ±0.1491, N=31; NMDA WT inPEP3: 
0.8096 ±0.0985, N=39). (B) Analysis of AMPA-normalized amplitude of NMDA f-EPSP component from transgenic 
and wild-type animals treated with PEP3 or inPEP3. No significant difference was observed among different 
experimental groups (NMDA Tg PEP3: 0.3307 ±0.03059, N=28; NMDA WT PEP3: 0.3930 ±0.3428, N=29; NMDA 
Tg inPEP3: 0.3889 ±0.4704, N=31; NMDA WT inPEP3: 0.3554 ±0.02845, N=39). (C) Analysis of Paired-pulse ratio 
protocol using AMPA-normalized area of NMDA f-EPSP component from transgenic and wild-type animals treated 
with PEP3 or inPEP3. No significant difference was observed among the different experimental groups (NMDA Tg 
PEP3: 1.225 ±0.1480, N=28; NMDA WT PEP3: 1.135 ±0.1276, N=29; NMDA Tg inPEP3: 1.114 ±0.08735, N=31; 
NMDA WT inPEP3: 1.256 ±0.09887, N=37). (D) Analysis of Input/Output protocol using NMDA f-EPSP peak 
component from transgenic and wild-type animals treated with PEP3 or inPEP3. No significant difference was 
observed among different experimental groups (NMDA fEPSP Tg inPEP3: -58.24 ±5.464, N=21; NMDA fEPSP WT 
inPEP3: -63.12 ±7.622, N=21). 
 
2.5. Treatment with PEP3 increases spines width and density  
 
To assess whether the PEP3 treatment could affect spine shape, using Dil membrane staining 
the morphology and density of spines in the hippocampus was analysed. Transgenic mice 
treated with inPEP3 showed a significant shrinkage of the spines compared to wild-type 
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mice. Interestingly, transgenic mice treated with PEP3 showed significantly increased 
dendritic spines width (Tg PEP3: 0.669 ±0.009, N=17) compared to APP/PS1 mice treated 
with inPEP3 (Tg inPEP3: 0.617 ±0.017, N=12) (Figure-12 A). Moreover, analysis of the 
different type of spines revealed that the percentage of mushroom spines drastically 
decreased in the transgenic mice treated with inPEP3 compared to wild-type mice. 
Interestingly, transgenic mice treated with PEP3 showed a significantly increased percentage 
of mushroom spines (Tg PEP3: 4.868% ±1%, N=15) compared to transgenic mice treated 
with inPEP3 (Tg inPEP3: 1.697% ±0.737%, N=10) (Figure-12 B).  
 
 
 
(Figure 12) Spine morphology investigation after treatment of APP/PS1 or wild-type mice with either PEP3 or 
inPEP3 (A) Representation of statistical analysis of dendritic spines width (µm). Transgenic mice treated with 
inPEP3 showed a significant decrease of spines width compared to wild-type mice (Tg inPEP3: 0.617 ±0.017, 
N=12; WT inPEP3: 0.707 ±0.011, N=23; One-way ANOVA ****p<0.0001). Transgenic mice treated with PEP3 
showed significantly higher spine width compared to transgenic mice treated with inPEP3 (Tg inPEP3: 0.617 
±0.017, N=12; Tg PEP3: 0.669 ±0.009, N=17; One-way ANOVA *p=0.0264). (B) Representation of statistical 
analysis of mushroom spines percentage. Transgenic mice treated with inPEP3 showed a significant decrease of 
mushroom spines percentage compared to wild-type mice (Tg inPEP3: 1.697% ±0.737%, N=10; WT inPEP3: 
26.60% ±4.682%, N=23; One-way ANOVA ***p=0.0004). Tg mice treated with PEP3 showed a significant increase 
in percentage of mushroom spines compared to transgenic mice treated with inPEP3 (Tg inPEP3: 1.697% 
±0.737%, N=10; Tg PEP3: 4.868% ±1%, N=15; One-way ANOVA ****p<0.0001). (C) Representation of statistical 
analysis of spines density (number of spines per 10µm long dendrite area). No significant difference of spine 
density was observed between transgenic mice treated with inPEP3 and wild-type mice. Significant increase of 
spine density was observed in transgenic mice treated with PEP3 compared to wild-type mice (WT inPEP3: 8.390 
±0.4157, N=23; Tg PEP3 Mean: 9.946 ±0.4122, N=17; One-way ANOVA *p=0.0246). (D) Panels showing potential 
changes in dendritic spines shape and count in regard of experimental groups. 
 
Regarding the overall spine density, the transgenic mice treated with inPEP3 have similar 
spine density to wildtype mice as no significant differences were observed between the two 
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groups. However, the transgenic mice treated with PEP3 showed a significant increase of 
spines density (Tg PEP3 Mean: 9.946 ±0.4122, N=17) compared to wild-type mice treated 
with inPEP3 (WT inPEP3: 8.390 ±0.4157, N=23) (Figure-12 C and D).These morphological 
changes in spines observed in the hippocampus of the mice treated with PEP3 could represent 
a functional mechanism by which the treatment improved APP/PS1 mice cognition since 
spine morphology is known to strongly correlates with cognitive performance.142 ADAM10 
has many substrates known to act as cell-adhesion molecules and therefore having important 
roles in spine and synapse morphological modulation.114 Among these substrates we 
investigated the effect of increased ADAM10 synaptic localization on the processing of APP 
and N-cadherin. Investigation of Notch processing was also performed as it is an important 
player in neurogenesis. 
 
2.6. PEP3 treatment increases endogenous sAPPa levels in 
APP/PS1 mice without changing N-Cadherin and Notch 
shedding 
 
 
To investigate the effect of PEP3 on the activity of the a-secretase towards APP, we measure 
the levels of Ab42 and sAPPa by ELISA. Interestingly no changes were observed in human 
Ab42 and human sAPPa levels in the cortex of transgenic mice treated with PEP3 (Figure-13 
A and B). This is likely to be due to the strong 3-fold overproduction of humanized APP in 
this mouse model together with the increase cleavage of mutated PS1 leading to 
overproduction of Ab42 peptide. Therefore, we hypothesized that PEP3 could not counteract 
the effect of the Swedish mutation on APP metabolism. However, to assess if ADAM10 
activity was increased by the treatment we measured mouse sAPPa levels in the 
hippocampus.  
 
The results obtained using a mouse/rat sAPPa ELISA kit showed a significant increase of 
sAPPa levels in APP/PS1 mice treated with PEP3 (PEP3: 14,02 ± 0,491, N=8) compared to 
transgenic mice treated with inPEP3 (inPEP3: 11,81 ± 0,658, N=7) (Figure-13 C). This 
interesting result suggests an increase of ADAM10 activity on the endogenous APP protein. 
In consideration of previous data observing no changes in humanized metabolites, this 
observation supports the action of PEP3 in increasing ADAM10 relative activity towards 
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APP, however its action is not enough to significantly change overexpressed humanized APP 
and overproduction of Ab1-42 caused by mutations in this model.  
 
 
(Figure 13) ELISA assays assessing metabolites levels in the cortex and hippocampus of the treated 6-month-old 
APP/PS1 mice with either inPEP3 or PEP3. (A) ELISA assays performed to assess Human Ab42 levels in the cortex 
of transgenic mice after treatment. No significant difference in Ab42 levels was observed in the transgenic mice 
treated with either active PEP3 or inactive PEP3 (Ab42 PEP3 Mean 11,01 ± 1,932, N=9; inPEP3 Mean: 9,88 ± 
0,927, N=9). (B) ELISA assays performed to assess Human sAPPa levels in the cortex of the transgenic mice after 
treatment. No significant difference was observed in the transgenic mice treated with either active PEP3 or inactive 
PEP3 (sAPPa PEP3 Mean: 4,670 ± 0,5401, N=9; inPEP3 Mean: 4,602 ± 0,5172, N=9) (C) ELISA assays performed 
to assess sAPPa levels in the hippocampus of the transgenic mice after treatment. Significant increase of sAPPa  
levels was observed in the transgenic mice treated with PEP3 compared to transgenic mice treated with inactive 
PEP3 (PEP3: 14,02 ± 0,491, N=8; inPEP3: 11,81 ± 0,658, N=7; t-test *p=0,0017). 
 
 
To assess ADAM10 activity, we measured also Notch and N-Cadherin cleavage. Analysis of 
Notch processing in 6-month-old APP/PS1 mice showed no difference between transgenic 
mice treated with the inPEP3 or PEP3. However, a trending decrease of the processing of 
Notch was observed in transgenic mice treated with inPEP3 compared to wild-type mice 
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treated with inPEP3 (Figure-14 A and B).  The processing of N-cadherin also showed no 
significant difference between transgenic mice treated with inPEP3 or PEP3. 
Nevertheless, a trend to a decrease of the processing of these proteins is observable when 
comparing the transgenic mice treated with the inPEP3 to the inPEP3-treated wild-type mice 
(Figure-14 C and D).   
 
 
 
 
(Figure 14) Substrates assessment after treatment of 6-month-old APP/PS1 and wild-type mice with either inPEP3 
or PEP3. (A) Levels of the synaptic Notch protein were assessed performing western blotting from TIF of forebrain 
of the treated transgenic mice. (B) OD quantification of WB experiment in A. No significant difference in Notch 
levels was observed between transgenic mice treated with PEP3 or inPEP3 (Tg inPEP3: 75.14% ±13.94%, N=7; Tg 
PEP3: 103% ±12.25%, N=9). (C) Levels of the synaptic N-cadherin protein were assessed performing WB from TIF 
of hippocampus of the treated transgenic mice. (D) OD quantification of WB experiment in C. No significant 
difference in N-cadherin CTF synaptic levels was observed between transgenic mice treated with PEP3 or inPEP3 
(Tg inPEP3: 70.93% ±18.95%, N=6; Tg PEP3: 100.6% ±15.40%, N=7). 
 
In light of these results, the increase in ADAM10 synaptic levels through the action of PEP3 
can be considered determinant to increase endogenous sAPPa and trigger morphological 
changes in spines, independently to its action towards other substrates as N-cadherin. The 
PEP3 agent showed interesting potential as therapeutic agent in the frame of AD. Therefore, 
improvement of its drug potential was decided. 
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3. PEP3 lacking TAT sequence is able to cross cells’ 
membrane and increase ADAM10 synaptic levels 
by interfering with the formation of 
ADAM10/AP2 complex  
 
 
In order to improve the druggability of the cell-permeable peptide PEP3, we have tested the 
capacity of the PEP3 without the TAT sequence (named 3R) to penetrate the cells. As control 
we used the inPEP3 sequence without TAT and we named it 3E.  
 
Indeed, modelling studies indicate that such sequences have an alpha-helical structure that 
can confer cell penetrance. Firstly, 3R peptide tagged with fluorescein was tested for its 
capacity to cross cell membranes. Cells were transfected with dsRed to detect cell 
morphology. Live imaging was performed to analyse the localization of the peptides.  
 
We used TAT peptide as positive control. Hippocampal neuronal culture from rat embryos 
were treated with the peptides at 1μM. Images show a clear penetration of TAT peptide into 
the cells, while 3R accumulate at the inner side of the plasma membrane site  
(Figure-15 A and B). 
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(Figure 15) Live imaging of cell penetration capacity of PEP3 lacking TAT sequence. (A) cells expressing DsRed 
were imaged after application of TAT PEP3 showing endogenous signal from the peptide fluorescein to colocalize 
inside the cells. (B) cells expressing DsRed were imaged after application of PEP3 lacking TAT sequence showing 
endogenous signal from the peptide fluorescein inside the cells. 
 
Secondly, the parameters of the efficacy of 3R peptide in targeting ADAM10 endocytosis 
were also assessed in-vitro on hippocampal neuronal culture from rat embryos. Treatment 
with these peptides at 1μM were applied on cells for 30 minutes. Co-immunoprecipitation 
was performed from the neuronal lysates to analyze the effect of the peptide on 
ADAM10/AP2 interaction, followed by western blotting to assess ADAM10 synaptic levels.  
Immunoprecipitation of ADAM10 revealed significantly lower levels of b2-adaptin, a-
adaptin and AP50 subunits of AP2 in the immunocomplex from cells treated with 3R when 
compared to cells treated with 3E (Figure-16 A and B). Data obtained with 3R were similar 
to previous in vitro laboratory work showing reduction of the ADAM10/AP2 complex 
interaction by 89% for α-adaptin subunit and by 78% for μ2-subunit when treating cells with 
TAT-containing PEP3 (Data not shown). Therefore, 3R has similar disruptive effect on 
ADAM10/AP2 complex as its TAT-containing equivalent PEP3.  
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Finally, these effects of 3R on the interaction led to an increase of ADAM10 synaptic levels, 
similar to what has been observed with the peptide PEP3 during in-vivo testing described 
above. 
Significantly higher levels of synaptic ADAM10 were observed in cells treated with 3R 
compared to cells treated with 3E (Figure-16 C and D). Overall, these outcomes demonstrate 
that the 3R peptide represents the starting point for the design of a new peptidomimetic 
compound able to improve the pharmacokinetics properties. 
 
 
 
 
(Figure 16) Efficacy assessment of PEP3 lacking TAT sequence, named 3R. (A) After treatment cells were lysated 
and immunoprecipitated using anti-ADAM10 antibody and AP2-subunits co-precipitation was evaluated. (B). 
Quantification of experiments in A. OD analysis showing treating cells with 3R significantly reduce co-
immunoprecipitation of ADAM10 with a-Adaptin, AP50 and b2-Adaptin (a-Adaptin 3R: 29.67 ±21.33, N=3, t-test 
*p=0.003; AP50 3R: 58.67 ±14.95, N=3, t-test *p=0.05; b2-Adaptin 3R: 15.39 ±8.358, N=3, t-test ***p=0.0005) 
compared to cells treated with 3E. (C) Representative immunoblot of ADAM10 WB analysis from cells TIF fraction. 
(D) Quantification of experiments in C. OD analysis showing significant increase of ADAM10 synaptic levels in cells 
treated with 3R compared to cells treated with 3E (ADAM10 3R: 145.9 ±47.60, N=5; ADAM10 3E: 38.21 ±13.19, 
N=7;t-test*p=0.0296. 
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AD is a very complex disease that represents a real challenge for drug development. Many 
drugs targeting the b-secretase have failed to improve cognition or have showed toxic side 
effects. Lately immunotherapies targeting Ab peptide have also been failing as Roche 
Holding and partners AC Immune SA have recently stopped late stage clinical trial for their 
antibody Crenezumab. These unsuccessful clinical trials for disease modifying agents traduce 
the deep complexity of understanding AD mechanisms. However, new advances have been 
made in developing agents that could pharmacologically up-regulate the activity of the a-
secretase ADAM10. Such promising compounds are currently in clinical trials and could 
represent potential new therapeutics in a close future. 
 
In light of these considerations, the results described in this thesis support the use of a-
secretase potentiator in AD. After observing promising in-vitro results with the CPP PEP3. 
This PhD project had for aim to test in-vivo the innovative peptide with the final objective of 
rescuing AD phenotype in a transgenic mouse model of the pathology. The results obtained 
during this project demonstrated that PEP3 is able to interfere with the association between 
ADAM10 and AP2 complex, and thereby to modify ADAM10 local trafficking and synaptic 
availability. Indeed, after a 14 days treatment of transgenic mice with the CPP, ADAM10 
synaptic availability was observed to be higher in these animals. These promising results led 
us to set up a series of experiments to assess the effect of this increase on AD mice at full-
blown pathology. At 9 month of age the transgenic mice treated with PEP3 showed a 
decrease in ADAM10/AP2 association and an increase in ADAM10 synaptic levels. 
Unfortunately, those changes induced by the peptide did not lead to an improvement of the 
strong phenotype of the APP/PS1 mice at full-blown pathology. This absence of effect on the 
phenotype might be due to the far too advanced stage of the disease in these mice. At this age 
the disease is to be considered severe as these mice present irreversible neuronal loss together 
with strong cognitive impairments. The treatment with PEP3, even though showing to trigger 
an increase of ADAM10 synaptic localization and modification in GluN2A subunit synaptic 
levels, is likely to have had too mild synaptic compensatory mechanisms to reverse the 
tremendous disturbance occurring at this stage of the disease, such as neuronal loss, gliosis 
and inflammatory response. Analysis of the metabolites resulting from APP processing 
revealed no changes in human soluble APPa levels suggesting no increase of a-secretase 
activity towards humanized APP. But paradoxically a decrease of mouse soluble Ab was 
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observed and could suggest either an increase of endogenous APP cleavage or an increase of 
Ab peptide clearance.  
 
In light of these promising results, decision was made to treat APP/PS1 mice with PEP3 at 
early stage of the disease to modify its progression and act on pathological mechanisms 
observed in previous studies such as synaptic loss and changes in synaptic transmission.143 A 
positive effect of PEP3 on synaptic loss could strongly improve the behavior of the mice, as 
spine density have been observed to correlate strongly with cognitive performance in AD 
patients.67 In order to treat the mice during the onset window of the disease we have screened 
APP/PS1 mice of different age. Screening of 3- and 6-month-old APP/PS1 revealed that 
ADAM10/AP2 association was already increased at 6-month-old but not yet changed at 3-
month-old. In the same manner, the decrease of ADAM10 synaptic levels was observed at 6-
month-old but no change was yet to be observed at 3-month-old. In light of these results, the 
age of 6-month-old represents an early stage of the disease correlating with the onset of 
ADAM10 local trafficking impairment in these mice. Therefore, we treated a new pool of 
APP/PS1 mice of 6-month-old to act on the disease progression as from its onset. 
Experiments at early stage, showed the same rescue of ADAM10 association and synaptic 
levels with PEP3 treatment, confirming the results previously obtained at full-blown 
pathology on the efficacy of the peptide to act on the a-secretase synaptic availability. In 
contrast to what was observed at full-blown pathology the treatment at early stage of the 
pathology leaded to a significant improvement of the phenotype of the transgenic mice. This 
behavioral readout obtained in a Novel Object Recognition Test was confirmed later in a Y-
maze test. Interestingly, the mice treated with the PEP3 displayed higher preference index for 
the novel object and arm translating an efficient recognition, learning and memory retention 
in these mice. The treatment clearly improved hippocampal function as this structure is 
supporting spatial memory, object recognition and learning processes involved in these 
behavior tasks. Interestingly a increase of the synaptic levels of GluN2A subunits together 
with a trending increase of GluN2B subunit of the NMDA receptors were observed in the 
hippocampus of the mice treated with PEP3. This represents a strong evidence of a 
therapeutic mechanism by which the peptide could increase synapses and restore deficits in 
synaptic transmission occurring in the transgenic mice. 
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In order to further investigate the effect of PEP3, we decided to repeat a new treatment on a 
different line of 6-month-old APP/PS1 mice during a secondment in JANSSEN 
pharmaceuticals and to assess via electrophysiology the effect of the peptide on the 
hippocampal synaptic activity. Field excitatory postsynaptic potential were recorded using 
MEA setups. Unfortunately, no synaptic deficits were observed in the transgenic mice as 
neither a cognitive deficit was observed in a V-maze test and nor a change in ADAM10 
synaptic levels after biochemical investigation. This showing the absence of the “synaptic 
traits” of the disease in this line of mice at this age as in this specific setup environment. 
Those data do confirm that the peptide is not toxic and acts specifically on the synaptic traits 
that are characteristic of the pathology. As no impairment of ADAM10 was present in those 
mice, the peptide did not show is therapeutic potential. However, in patients presenting those 
AD-specific synaptic deficits, the treatment could have a deep disease modifying impact. 
 
Decision was taken to further analysis mice previously treated in Milan to screen functional 
changes in the hippocampus. Morphological analysis revealed a shrinkage of the spines and a 
drop of the number of mushroom spines in the hippocampus of the transgenic mice. 
Treatment with PEP3 rescued the deficit in synaptic size and density observed in the 
transgenic mice which is in accordance with the previously observed, increase of synaptic 
GluN2A and GluN2B subunit levels in the hippocampus. The metabolites were also changed 
as an increase of mouse sAPPa was observed in mice treated with PEP3 which could trigger 
an increase in hippocampal synaptic density and an improvement of memory as observed in 
previous studies.144 No changes in human sAPPa levels were observed. Similar to treatment 
at full-blown pathology, the effect of the PEP3 at early stage of the disease could shift 
endogenous APP processing, but the strong mutation bearing in the transgenic mice and their 
effects such as overexpression of humanized APP and upregulation of b-secretase activity, 
could not be counteracted.  Supporting this hypothesis, absence of changes in humanized 
metabolites such as human soluble APPa and human soluble Ab was observed after 
treatment at early stage. 
In conclusion, we demonstrated that the administration of PEP3 in a mouse model of AD at 
early stage interferes with ADAM10/AP2 complex formation and increase the synaptic 
availability of ADAM10. This led to an increase of the sheddase’s activity towards APP as 
increased of endogenous mouse sAPPa was observed. In AD patients, this causality between 
ADAM10 activity and sAPPa levels could also hypothetically lead to the use of sAPPa 
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levels in CSF as biomarker of ADAM10 synaptic activity. In our experiment, the increase in 
mouse sAPPα level suggests a shift of APP metabolism towards the non-amyloidogenic 
pathway. Moreover, this increase of soluble APPa triggered compensatory mechanisms 
leading to improvement of synaptic organization in the hippocampus. Results observed 
suggest an increase of spine width, mushroom spines and overall spine density together with 
increase of synaptic GluN2A and GluN2B containing NMDAR in the hippocampus. 
Therefore, the use of PEP3 can be considered as a potential disease-modifying tool since it 
can affect the primary mechanism of AD pathogenesis at the synapse, and could via its rescue 
of spine morphology and density improve synaptic transmission and in fine alleviate 
cognitive impairments related to the disease progression.  
The second aim of the thesis was to enhance the drugability of the agent. With this objective, 
a specific PEP3 lacking the TAT sequence was created and tested in-vitro. This peptide was 
able to penetrate the cells and supposedly interact with the target as observed by live imaging. 
As its equivalent containing the TAT sequence, the peptide lacking the TAT sequence is able 
to interfere with the ADAM10/AP2 protein complex. And this effect is leading to a 
significant increase in ADAM10 synaptic availability. These effects are expected to be 
followed by mechanisms observed during in-vivo testing. The future objective is to test this 
peptide in-vivo and assess its potential curable effect on AD mouse models. 
To conclude enhancing the action of ADAM10 on the amyloid cascade represent a serious 
therapeutic strategy. The action of PEP3 on the endocytosis of the sheddase in order to 
increase its synaptic availability without affecting its systemic activity represents a clever and 
promising strategy to enhance the activity of the secretase in the frame of AD. In order to 
fully validate this strategy to be used in patients, further investigation on ADAM10 function 
and partners is needed. The sheddase ADAM10 has many substrates that should be further 
studied as they could also impact the course of the disease as a downstream effect of the 
PEP3-mediated upregulation of the sheddase activity. Important substrates like N-cahderin 
that could impact cell adhesion and Notch that could impact neurogenesis need to be further 
studied for their interaction with ADAM10. Finally, the most important point to clarify is the 
implication of the sheddase in the cross-talk between Aβ and the synaptic function. 
Understanding the mechanisms of this interaction is essential to counteract the synaptic loss 
induced by Aβ. 
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The synaptic dysfunction observed in AD drives the cognitive decline and are known to 
precede neuronal death. Therefore, the deficit in synaptic transmission is not only a 
consequence of cell death but a real drive for the pathology. Impairments of ADAM10 local 
trafficking is associated with synaptic failure related to Aβ as it has been observed in AD 
patients and confirmed in this study on APP/PS1 mice. 
In conclusion, the impairment of ADAM10 synaptic trafficking in AD patients could have a 
strong negative impact on the synapse, in this sense we need to better understand the role of 
the sheddase as an important player of the synapse.  
The comprehension of the molecular pathways underlying Aβ-induced synaptic dysfunction 
and their interconnection with ADAM10 activity is essential in order to develop an 
innovative agent targeting directly the pathogenic mechanisms of the disease. 
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PhD Research activity 
 
Student Name: Sébastien Therin 
Student Number: R11498 
TUTOR: Prof. Monica Di Luca 
CO-TUTOR: Prof. Elena Marcello 
COORDINATOR: Prof. Alberico L. Catapano 
Academic years: 2017-2018
 
 
Poster presentations: 
 
1 European Synapse meeting (ESM), December 2017, MILAN, ITALY 
S. Therin, S. Musardo, F. Seibt, A. Ribeiro, D. Di Marino, C. Balducci, G. Forloni, V. Grieco, 
C. Giudice, F. Gardoni , J. Pita-Almenar, M. Di Luca, E. Marcello. An innovative tool to 
modulate ADAM10 synaptic localization and activity in a mouse model of Alzheimer’s 
disease.  
 
2 Federation of European Neuroscience societies (FENS), July 2018, BERLIN, GERMANY 
S. Therin, S. Musardo, F. Seibt, A. Ribeiro, D. Di Marino, C. Balducci, G. Forloni, V. Grieco, 
C. Giudice, F. Gardoni , J. Pita-Almenar, M. Di Luca, E. Marcello. An innovative tool to 
modulate ADAM10 synaptic localization and activity in a mouse model of Alzheimer’s 
disease.  
 
3 American Society for Neuroscience (SfN), November 2018, SAN DIEGO, USA 
S. Therin, S. Musardo, F. Seibt, A. Ribeiro, D. Di Marino, C. Balducci, G. Forloni, V. Grieco, 
C. Giudice, F. Gardoni , J. Pita-Almenar, M. Di Luca, E. Marcello. An innovative tool to 
modulate ADAM10 synaptic localization and activity in a mouse model of Alzheimer’s 
disease. 
 
Data presentations: 
 
 
 
 
University of Milan 
June 15th 2016 
Data presentation during “Next step 7” conference. 
(200 people) 
DZNE, Bonn, Germany 
May 9th-10th 2017  
SyDAD Annual meeting Data presentation for EU committee. 
(European committee + SyDAD commitee) 
University of Milan 
April 26th-28th 2017 
Data presentation during PhD Spring Camp in Gargnano.  
(50 people) 
University of Milan 
June 15th 2017 
Data presentation during “Next Step 8” conference. 
 (300 people) 
University of Milan 
April 7th-8th 2018. 
SyDAD annual Meeting Data presentation. 
(European committee + SyDAD commitee)  
University of Milan 
April 14th 2018 
Skype Data presentation during PhD Spring Camp. 
(50 people) 
Bordeaux, France 
July 7th-11th 2018 
SyDAD final annual Meeting Data presentation. 
(European committee + SyDAD commitee) 
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Attended courses/workshops: 
 
2016 
• Kick-off Meeting, Karolinska Institutet, April 21th-22th. 
• Innovation Workshops, Serendipity Innovations and Axon Neuroscience, April 23th.  
• Alzheimer Disease Course, Karolinska Institutet, April 25-29th. (ETCS 1,5) 
• Transversal competence courses, Course A: Open access, University of Milan, September 26th.  
• Transversal competence courses, Course B: Evaluation of research, University of Milan, October 3rd. 
• Pharmacological properties of biotechnological drugs, University of Milan, June 14-17th. (ETCS 2) 
•  Advanced analytical approaches in clinical and experimental pharmacology, University of Milan, July 
4th- 7th. (ETCS 2) 
2017 
• Synapse Methodology course Bordeaux, January 18-26th. (ETCS 1,5) 
• Drug Discovery Course, Axon Neuroscience, March 26-28th. (ETCS 1,5) 
• Molecular biology Course, University of Milan, 19th June; 4th July and 10th July. (ECTS 1) 
• Genetic toxicological issues and methodological approaches in vitro and in vivo, University of Milan, 
July 13th. (ECTS 2) 
• Neuropsychopharmacology Course, University of Milan, July 21th. (ECTS 2) 
2018 
• Workshop Project Management and career plan, University of Milano, May 9th. (ETCS 1) 
 
Other activities & Outreach activities: 
 
• Italian language course, University of Milan, September 2016 – February 2017. 
• Introduction of pharmacology to the public at department booth during the European 
Researcher night, Milan September 2017 
• Representing SyDAD program at European corner during the European Researcher 
night, Milan, September 2018. 
• Teaching at Workshop on Advanced Methods for Preclinical Alzheimer Disease 
Research, Bordeaux School of Neuroscience, January 21th-February 2nd, 2019. 
Patent and Publication in preparation: 
 
Patent application: 
 
Inventor in the Italian Patent Application No.102017000149130 filed on 22/12/17. 
Under review for extension of the patent protection to US and Chinese regulatory agencies. 
 
"Peptides able to activate ADAM10 enzyme, adequate for treatment of diseases characterized by an 
increased amyloid beta peptide production” 
 
Publication combining PhD Data in preparation: 
 
“Use of a Cell Permeable Peptide to modulate ADAM10 synaptic localization and activity in a mouse 
model of Alzheimer’s disease” 
 
PhD Secondment: 
 
8 months PhD secondment in Janssen Pharmaceutica in Belgium: Electrophysiological assays following 
intraperitoneal administration of CPPs in APP/PS1 mice. 
 
